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ungi are everywhere: we inhale the spores from the air, we get in contact with
them through the environment (via food, animals, plants, and soil), and they
are present in the human body itself. With the growing number of immunocompro-
mised patients due to aggressive cancer treatment and immunosuppressive treat-
ment after organ and stem cell transplantation, invasive fungal infections have in-
creasingly challenged our health care system.
1.1 Invasive fungal infections
Both molds and yeasts can cause invasive fungal infections. Molds are a type
of fungus that has a tendency to grow with help of multiple celled filaments called
hyphae, whereas yeasts grow as a singe cell. The most common invasive fungal
infections are invasive aspergillosis (mold) and invasive candidiasis (yeast). Inva-
sive aspergillosis is the leading cause of infection-related deaths in patients with
acute leukemia and in stem cell transplant recipients [1]. Aspergillus fumigatus is
the most common species recovered from cases of invasive aspergillosis. The po-
tentially infectious conidia or spores of the Aspergillus species are inhaled from the
air. Spores of the Aspergillus fumigatus have a maximal cross-sectional diameter of
only 2-3 µm and may therefore diffuse easily to distal human airways. Humans
typically inhale around 200 spores daily, depending on the environment [2]. De-
molitions of old buildings and certain rural settings have the highest numbers of
colony-forming units of Aspergillus per m3 of environmental air. However, hospital
rooms with high-efficiency particulate air filtration still have measurably quantities
of Aspergillus spores [3]. In healthy persons, the spores are disarmed by the immune
system. Mucociliary clearance is achieved by ciliated bronchial cells and goblet cells
in the airways. Spores that are not removed by mucociliary clearance encounter
alveolar macrophages and dendritic cells that are responsible for the killing of the
spores, as well as the initiation of a proinflammatory response that recruits neu-
trophils from the blood stream. Neutrophils are able to destroy the fungal hyphae
resulting in fungal killing [2].
However, in immunocompromised patients, such as patients with neutropenia
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Figure 1.1: Infectious life cycle of Aspergillus fumigatus. Aspergillus is ubiquitous in the envi-
ronment and asexual reproduction leads to the production of airborne conidia. Inhalation by
immunocompromised patients results in conidium establishment in the lung, germination,
and either polymorphonuclear cell (PMN)-mediated fungal control with significant inflam-
mation (in patients with corticosteroid therapy) or uncontrolled hyphal growth with a lack of
PMN infiltrates and, in severe cases, dissemination (in patients with neutropenia). Adapted
from Dagelais & Keller, 2009 [2].
as a result of chemotherapy or underlying hematologic disease, patients receiving
immunosuppression to prevent rejection after organ or stem cell transplantation,
patients with HIV/AIDS, and in patients with preexisting structural lung disease,
these spores can lead to pulmonary aspergillosis (Figure 1.1). The Aspergillus spores
can penetrate into the lung tissue and enter the bloodstream via the distal airways
and alveolar spaces of the lung, resulting in invasive aspergillosis. A poorly con-
trolled aspergillosis infection can disseminate throughout the body and can infect
major organs including the liver, kidneys, and the brain [1, 2]. A crude mortality of
invasive aspergillosis of 37 to 49% is seen in adult patients [4, 5]. In immunocom-
promised children with invasive aspergillosis, an overall mortality of 18 to 53% is
found [6, 7].
Invasive candidiasis is caused by the Candida species, which are part of the mi-
crobiological flora of our skin, gastrointestinal and genitourinary tract, and are also
found in the environment. Candida albicans is the species which is seen most fre-
quent in humans. When the skin and gastrointestinal barriers loose their integrity,
Candida species from the skin or gastrointestinal tract can migrate into the blood










Figure 1.2: The development of invasive candidiasis. Candida species from the skin and gas-
trointestinal and genitourinary tract can migrate into the blood (candidemia) and disseminate
from the blood to other organs. Adapted from Eggiman et al. 2003 [8].
(candidemia). In disseminated candidiasis, the infection is migrated from the blood
to other organs, such as the liver, kidneys, and eyes (Figure 1.2) [2].
Invasive candidiasis is most frequent in immunocompromised hosts and criti-
cally ill patients, and risk factors include a prolonged stay in an intensive care unit
(ICU), the use of a central venous catheter, parental nutrition, mechanical ventila-
tion, previous broad spectrum antibiotic therapy (resulting in overgrowth of Can-
dida), immunosuppression, or a recent surgery [8–11]. A crude mortality of 31 to
61% is seen in adult patients with invasive candidiasis [12–16]. In children, a mor-
4 Chapter 1
tality rate of 16 to 29% is found [12, 16–20]. Furthermore, invasive aspergillosis and
candidiasis are both associated with a prolonged hospital stay of 10 to 23 days and
increased costs [5, 6, 12, 21].
Other invasive fungal infections are cryptococcal infections, for example cryp-
tococcal meningitis, which is mostly seen in patients with HIV/AIDS and patients
who underwent organ transplantation [22]. Severely immunocompromised patients
are also vulnerable to infections with unusual fungi that are present in the envi-
ronment. These infections, such as zygomycosis and hyalohyphomycosis, are less
common and have a high mortality of 50 to 95% [23].
1.2 Antifungal treatment
Several classes of antifungal drugs are available for the treatment of invasive fun-
gal infections, the polyenes (amphotericin B), the azoles (voriconazole, posacona-
zole, itraconazole, and fluconazole), the echinocandins (caspofungin, micafungin,
and anidulafungin), and a residual group including flucytosine. The different classes
of antifungal drugs have different mechanisms of action. The polyenes and azoles
disrupt the fungal cell membrane, the echinocandins inhibit the formation of the
fungal cell wall, and flucytosine interferes with the DNA synthesis of the fungal cell
(Figure 1.3) [24, 25]. The polyenes have a broad spectrum of activity that includes
molds and yeasts. The susceptibility of the triazoles is more variable and depends
on the specific agent. Fluconazole, for example, has no activity against Aspergillus
species. The echinocandins are active against most Aspergillus and Candida species,
but lack activity against Cryptococcus and Fusarium species [26].
The guidelines of the Infectious Diseases Society of America (IDSA) and the
Dutch Working Party on Antibiotic Policy (SWAB) for the treatment of aspergillo-
sis recommend voriconazole as primary treatment for invasive aspergillosis. For
patients refractory to or intolerant of voriconazole, therapy with amphotericin B,
caspofungin, or posaconazole are recommended. For prophylaxis against invasive
aspergillosis in neutropenic patients with acute leukemia and in stem cell transplant
recipients, posaconazole is the first choice treatment. It is recommended that treat-
ment of invasive aspergillosis should be continued for a minimum of 6 to 12 weeks.
In immunosuppressed patients, therapy should be continued throughout the period
of immunosuppression and until lesions have resolved [28, 29]. The IDSA, SWAB,
and European Society for Clinical Microbiology and Infectious Diseases (ESCMID)
guidelines for the management of candidiasis recommend an echinocandin or am-
photericin B in neutropenic patients, with fluconazole or voriconazole as an alterna-
tive. For nonneutropenic patients, fluconazole or an echinocandin are primary ther-
apy, amphotericin B is an alternative. Fluconazole and posaconazole are advised
















Fungal cell Cell membrane and cell wall
Figure 1.3: The pharmacology of antifungal drugs. The polyenes act by binding to ergosterol
in the fungal cell membrane, resulting in depolarization of the membrane and formation
of pores that increase permeability, eventually leading to cell death. The azoles inhibit the
fungal cytochrome P-450 dependent enzyme 14-alpha demethylase, thereby interrupting the
synthesis of ergosterol. Inhibition of the ergosterol synthesis pathway leads to the depletion
of ergosterol in the cell membrane, causing increased membrane permeability and inhibition
of fungal growth. The echinocandins block the fungal cell wall synthesis by inhibiting the
enzyme 1,3-β-glucan synthase. Inhibition of this enzyme results in depletion of β-glucan
polymers in the fungal cell, resulting in an abnormally weak cell wall. Flucytosine interferes
with the DNA and RNA synthesis of the fungal cell. Adapted from Dodds Ashley et al.
2006 [27].
as prophylaxis in neutropenic patients, organ or stem cell transplant recipients, and
in patients in the ICU (Table 1.1). The recommended duration of treatment of can-
didemia is 2 weeks after documented clearance of Candida from the bloodstream
and resolution of symptoms and neutropenia. In patients with disseminated can-
didiasis, the duration of the treatment depends on clinical findings and resolution
of radiological abnormalities and is at least 6 weeks [29–32, 32].
Cryptococcal meningitis should be treated with amphotericin B plus flucytosine
for at least 2 weeks. When the disease is stable, the treatment can be continued
with fluconazole for a total of at least 10 weeks [22, 29, 33]. For the treatment of
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Table 1.1: Treatment of invasive fungal infections [20, 28–32, 32].
Primary treatment Alternative treatment Prophylaxis
Invasive Voriconazole Amphotericin B Posaconazole
aspergillosis Caspofungin
Posaconazole
Invasive Neutropenic Neutropenic Fluconazole





1 Choose an echinocandin (caspofungin, micafungin, or anidulafungin) for critically ill or unstable
patients [29, 30].
2 In children fluconazole or amphotericin B, and caspofungin as an alternative [20, 29].
zygomycosis, amphotericin B is advised. For salvage treatment on failure or in-
tolerance of amphotericin B, posaconazole can be considered [29]. Voriconazole is
recommended as first-line treatment for hyalohyphomycosis with Fusarium or Sce-
dosporium species [23].
1.3 Pharmacokinetics and pharmacodynamics
Whereas pharmacokinetics studies the absorption, distribution, metabolism, and
excretion of a drug by the body, pharmacodynamics explores the pharmacological
effect of the drug on the body. In case of invasive fungal infections, pharmacody-
namics studies the activity of the drug against the fungal pathogen. Pharmacokinet-
ics and pharmacodynamics (PK/PD) together describe the exposure to the drug and
the antifungal effect of the drug. The most common PK/PD indices in antimicrobial
therapy are the ratio of the area under the concentration-time curve (AUC) over 24
hours to the minimum inhibitory concentration (MIC), the percentage of the dosing
interval in which the concentration of the drug exceeds the MIC, and the ratio of the
maximal concentration to the MIC [34, 35].
Resistance to antifungal drugs can occur as a result of antifungal pressure with
the azoles by applying these antifungal drugs to protect crops against fungal infec-
tions and by adding azoles in wall paint products. Fungi such as Aspergillus may
develop drug resistance by selective pressure, facilitating survival of drug-resistant
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mutants by exchanging genetic material. Furthermore, resistance can occur as a
result of selection of less-susceptible subpopulations due to suboptimal antifungal
drug exposure in the human body [34]. Antifungal resistance has consequences in
terms of elevated MICs that are associated with poorer outcomes and breakthrough
infections during antifungal treatment and prophylaxis [36, 37]. Antifungal drug
susceptibility testing is therefore an essential component of the PK/PD target and is
important to optimize the antifungal treatment.
1.4 Critically ill patients
Prompt initiation of antifungal therapy in the appropriate dose is required to
improve outcome in patients with invasive fungal infections [25, 38–40]. However,
when drugs are registered, severely ill patients are most often not included in reg-
istration studies by the manufacturer of the drug. Hence, it is often unknown if the
recommended dose is also suitable for these critically ill patients. Due to alterations
in function of various organs and body systems in this patient group, the pharma-
cokinetics and the plasma concentration of the drug can be different [34, 35, 41–44].
Underexposure to the required drug can occur as a result of an increased volume of
distribution. Fluid extravasation as a result of endothelial dysfunction and capillary
leak, edema in sepsis and trauma, ascites, fluid resuscitation, and hyper-hydration
can all lead to dilution of the drug in plasma or extracellular fluids and lower drug
concentrations, in particular of hydrophilic drugs such as fluconazole. Furthermore,
enhanced renal clearance as a result of an increased cardiac output (leading to in-
creased renal blood flow) is seen in patients with burns, hyperdynamic conditions
during sepsis, use of hemodynamically active drugs, and hypoalbuminemia. Hy-
poalbuminemia leads to an increased unbound fraction of a drug, making it avail-
able for elimination. On the other hand, reduced renal clearance due to renal impair-
ment, as a result of the underlying disease or iatrogenically induced by nephrotoxic
comedication, can result in drug overexposure [34, 35, 41, 43, 44]. Besides, hepatic
dysfunction is also often present in critically ill patients. Advanced liver disease,
decreased hepatic blood flow, and impaired metabolic activity (for example due to
inflammation [45]) can result in overexposure of mainly hepatically metabolized
drugs such as voriconazole. Other alterations that may impact the pharmacokinetics
of drugs in critically ill patients are gastrointestinal, respiratory, and cardiovascular
failure (Figure 1.4) [42,44]. Finally, concomitant use of other drugs or substances can
give pharmacokinetic interactions and influence antifungal drug exposure [46].
The aforementioned altered pharmacokinetics of drugs also applies to critically
ill children and infants [47]. Besides, developmental changes in renal and hepatic
function, the gastrointestinal tract, and body composition can contribute to a vary-
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ing drug concentration with age [48,49]. Children are typically not included in regis-
tration studies and the recommended childrens dose is extrapolated from the adult
dose, which may result in decreased efficacy or toxic effects of antifungal drugs.
1.5 Therapeutic Drug Monitoring
Since different underlying pathophysiological or iatrogenic situations, that in-
fluence the pharmacokinetics of a drug, often coexist in the same patient, the phar-
macokinetic variability may therefore become even more unpredictable in critically
ill patients and the required PK/PD target may not be reached. Due to the vari-
able intra- and interindividual pharmacokinetics in critically ill patients, therapeutic
drug monitoring (monitoring of drug concentrations in blood/body fluids and sub-
sequent dose adjustment, TDM) can be useful to ensure patients achieve target drug
concentrations and prevent toxicity [35, 41]. Research has been shown that TDM of
voriconazole, posaconazole, itraconazole, and flucytosine may improve treatment
outcome with reduced toxicity. TDM is therefore recommended in several guide-
lines for the treatment of invasive fungal infections [20, 26, 28, 30, 31, 37, 38, 50, 51].
The utility of TDM of fluconazole and the echinocandins needs to be further ex-
plored.
1.6 Aim of the thesis
Adequate initial dosing regimens and subsequent TDM can be useful to ensure
adequate drug exposure in the critically ill patient, resulting in improved efficacy
and safety of the treatment. The first objective of this thesis is to evaluate the ex-
posure to antifungal drugs and to establish the relation with the outcome of the
antifungal treatment in critically ill adults and children. The second objective is to
gain a better insight into the pharmacokinetics and exposure of antifungal drugs in
critically ill patients with invasive fungal infections. The third objective is to develop
noninvasive sampling methods for performing TDM.
1.7 Outline of the thesis
In the first part of this thesis, the influences on the exposure of fluconazole and
posaconazole will be evaluated using TDM. Furthermore, the relation of the drug
exposure with the treatment outcome will be established. Finally, this part of the the-
sis includes the development of noninvasive sampling methods to perform TDM of
the azoles at home and in hospitals without an advanced bio-analytical infrastruc-
ture.
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- Reduced motility and perfusion
- Altered pH of enteral secretions
- Abnormal diet —> decreased absorption
- Enteral feeding solutions —> altered pH + binding to drugs
- Loss of enteral route of administration
Hepatic dysfunction
- Alterations in CYP enzyme activity
- Reduced hepatic blood ow
- Hypoalbuminemia
Renal failure
- Reduced drug excretion
- Fluid retention
- Acid base disturbance
- Renal replacement therapy
Cardiovascular failure
- Reduced perfusion gastrointestinal tract
- Reduced liver and kidney perfusion
- Fluid retention
- Metabolic acidosis
Sepsis / Septic shock:
- Fluid resuscitation —> increased body water
- Capillary leak syndrome
- Reduced peripheral tissue perfusion
- Increased cardiac output —> increased renal blood ow
- Hypoalbuminemia
- Inammation —> reduced CYP enzyme activity
- Endocrine dysfunction
Drug-drug interaction
- Alterations in CYP enzyme activity
- Altered stomach pH 
- Nephrotoxicity —> decreased renal function
Endothelial failure 
- Increased total body water
- Hypoalbuminemia
Respiratory failure
- Acid base disturbance
- Hypoxemia and metabolic acidosis
- Mechanical ventilation —> reduced cardiac output
Figure 1.4: Alterations in function of various organs and body systems that can influence the
pharmacokinetics of drugs in critically ill patients. Adapted from Power et al. 1998 [42].
• The objective of Chapter 2 is to determine the clinical variables that are associ-
ated with the serum concentration of fluconazole in critically ill children and
infants, and to identify which patient groups are at risk for underexposure of
fluconazole. Besides, the relation between the fluconazole concentration and
the time to culture conversion will be assessed.
• The goal of Chapter 3 is the development and clinical validation of a liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method of analysis
to determine the fluconazole concentration in oral fluid in children and infants.
• In Chapter 4 we establish risk factors for underexposure of posaconazole in
adult cancer patients and organ transplant recipients. Furthermore, we de-
termine the relation between the posaconazole serum concentration and the
outcome of the treatment.
• The objective of Chapter 5 is to develop and clinically validate a dried blood
spot analysis for the azoles voriconazole, fluconazole, and posaconazole. Ad-
ditionally, we evaluate the patients opinion on the sampling method.
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The second part of the thesis focuses on the pharmacokinetics and exposure of
caspofungin in critically ill patients.
• The goal of Chapter 6 is developing a method of analysis for the determination
of caspofungin in plasma with LC-MS/MS.
• In Chapter 7 we describe the caspofungin exposure at two different dosing
regimens in a patient with hepatic dysfunction.
• The objective of Chapter 8 is to investigate the pharmacokinetic parameters,
the exposure, and the optimal dose of caspofungin in ICU patients and to de-
termine the correlation of the caspofungin exposure with disease severity.
In Chapter 9 a general discussion and future perspectives are provided.
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Chapter 2
Insufficient fluconazole expo-
sure in pediatric cancer patients and the need
for therapeutic drug monitoring in critically ill
children
Abstract
Background. Fluconazole is recommended as first-line treatment in invasive candidiasis
in children and infants. Although timely achievement of adequate exposure of flucona-
zole improves outcome, therapeutic drug monitoring is currently not recommended.
Methods. We conducted a retrospective study of critically ill children treated with flu-
conazole from January 2007 to October 2013 and for whom fluconazole concentrations
were available. We collected demographic, clinical and treatment data through review
of the medical records and determined the correlation of clinical variables with the flu-
conazole concentration. Additionally, we assessed the relation between the fluconazole
concentration and the time to culture conversion in patients with proven invasive can-
didiasis.
Results. In total, 99 pediatric patients met the inclusion criteria. The fluconazole con-
centration was considered subtherapeutic in 40% of the patients. Multiple linear regres-
sion analysis showed a significant, independent and positive association of the flucona-
zole trough concentration with the fluconazole dose (P < 0.001), weight (P = 0.009) and
the serum urea concentration (P = 0.003), and a significant, independent and negative
association with age (P = 0.004) and cancer as underlying condition (P = 0.003). A
higher fluconazole concentration was associated with a shorter time to culture conver-
sion (hazard ratio = 1.076 [95% confidence interval, 1.017-1.138]; P = 0.011).
Conclusions. The fluconazole concentration is not sufficient in pediatric cancer patients
with the currently recommended dose regimen and a higher fluconazole dose is required
to achieve adequate drug exposure. Therapeutic drug monitoring of fluconazole can be a
valuable tool to detect possible underexposure in critically ill children.
2.1 Introduction
I
nvasive candidiasis (IC) is an important cause of morbidity and mortality in crit-
ically ill pediatric patients. Despite antifungal therapy, a mortality rate of 16 to
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29% and a mean 21-day increase in length of hospital stay are observed in pediatric
patients with IC [1–5]. Furthermore, in pediatric cancer patients with invasive fun-
gal infections a 5- to 26-fold increased risk of death is seen [3]. Risk factors for IC
include a prolonged length of stay in an intensive care unit (ICU), the use of a central
venous catheter, total parenteral nutrition, mechanical ventilation, dialysis, previous
broad-spectrum antibiotic therapy, immunosuppression, and recent surgery [6,7]. A
fluconazole dose of 6-12 mg/kg/day is advised in the Summary of Product Char-
acteristics (SPC) of fluconazole for the treatment of IC in pediatric patients [8]. The
guideline of the Infectious Diseases Society of America (IDSA) for the management
of candidiasis and the European Society of Clinical Microbiology and Infectious Dis-
eases (ESCMID) pediatric guideline recommend the use of fluconazole as first-line
therapy for (suspected) IC in children and infants. To achieve drug exposure com-
parable to adults, a fluconazole dose of 8-12 mg/kg/day is advised for children and
a dose of 12 mg/kg/day for neonates [9, 10].
In vivo studies have demonstrated that the pharmacokinetic/pharmacodynamic
parameter of fluconazole that best predicts outcome is the area under the concen-
tration - time curve (AUC) over 24 hours in steady state divided by the minimum
inhibitory concentration (MIC) [11,12]. An AUC/MIC ratio≥ 50 for Candida species
with MIC breakpoint ≤ 8 mg/L corresponds with a favourable outcome, requiring
an AUC of ≥ 400 mg*h/L [13–15]. Meanwhile, a higher AUC target of 800 mg*h/L
in immunocompromised and critically ill patients with IC may be preferred [16,17].
Although timely attainment of the target AUC improves outcome, therapeutic drug
monitoring (TDM) of fluconazole is currently not recommended [10,18], mostly due
to the linear dose-concentration relationship [19, 20] and the good safety profile of
fluconazole [21]. However, in critically ill patients, alterations in function of various
organs and body systems may influence the pharmacokinetics and, hence, affect the
serum concentration of a drug [22–26]. The purpose of this study was to determine
which patient characteristics and clinical variables are associated with the serum
concentration of fluconazole in critically ill pediatric patients and to identify which
patient groups are at risk for underexposure of fluconazole.
2.2 Methods
2.2.1 Study design and data collection
This retrospective study was conducted at the University Medical Center Gronin-
gen, a university hospital in the Netherlands with a 150-bed pediatric department,
including a pediatric and neonatal ICU. TDM of antimicrobial drugs is routinely
performed in critically ill patients in our hospital. Patients were eligible for inclu-
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sion if the following criteria were met: (1) age 0-18 years, (2) admission to a pediatric
ward or pediatric/neonatal ICU between 1 January 2007 and 30 September 2013, (3)
treatment with fluconazole, and (4) at least 1 steady state trough serum concentra-
tion of fluconazole available, which is after 2 days when a loading dose is given,
and after 5 days without a loading dose [15, 27]. This study was evaluated by the
local ethics committee (Institutional Review Board 2013-491) and was, according to
Dutch law, allowed due to its retrospective nature.
Data were collected through review of the medical records using a standard-
ized case report form. Demographic and clinical data were collected including age,
sex, weight, underlying condition, stay in an ICU, renal function (serum urea and
serum creatinine concentration), leukocyte count, Candida species and MIC, site of
infection, and the time to culture conversion. The presence of risk factors for IC
were reviewed, including the presence of a central venous catheter, total parenteral
nutrition, mechanical ventilation, dialysis, previous use of broad-spectrum antibi-
otics, and cytostatic and immunosuppressive therapy. Medical data were collected
on fluconazole dose (mg/kg/day) and route of administration, fluconazole trough
concentration, dose adjustments, and interacting comedication.
2.2.2 Correlations with fluconazole concentration
Fluconazole serum concentrations were determined using a previously validated
liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay and exter-
nally confirmed by proficiency testing [28, 29]. Data from pharmacokinetic studies
with both trough and AUC data of fluconazole in critically ill children and infants
with (suspected) IC were pooled to establish the threshold for an adequate trough
concentration. The adequate trough concentration was established by interpolating
pharmacokinetic data from the publications of Lee et al. [27] and Wade et al. [16] us-
ing an AUC of 400 mg*h/L (Pearson correlation coefficient trough and AUC of .994;
P = 0.006). A trough concentration of fluconazole > 11 mg/L was defined as an ad-
equate concentration and considered to be representative of an AUC ≥ 400 mg*h/L
in critically ill children and infants with (suspected) IC [16, 27, 30].
We assessed the correlation of the serum concentration of fluconazole with fac-
tors that can influence the pharmacokinetics of fluconazole, such as the patients‘
age, weight, and renal function (serum urea and serum creatinine concentration).
The correlation of the fluconazole dose with the serum concentration of fluconazole
was assessed as well. Furthermore, we compared the fluconazole concentration be-
tween patient groups with different underlying conditions (solid organ transplant
[SOT], cancer, surgery, and prematurity), sex, the presence of dialysis, the stay in
an ICU, the route of administration of fluconazole, and interacting comedication.
Finally, we performed a multiple linear regression analysis to assess the relation be-
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tween the fluconazole concentration and several explanatory variables. Variables
having a P value < 0.10 in the univariate analyses and variables that can theoreti-
cally indicate altered pharmacokinetics were included in the analysis.
2.2.3 Time to culture conversion
Time to culture conversion was defined as the time from the start of the flu-
conazole treatment to the first negative culture of the same matrix. Only patients
with a proven invasive fungal disease, according to the 2008 definition of inva-
sive fungal disease from the European Organization for Research and Treatment
of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute
of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consen-
sus Group [31], were included in the analysis. Furthermore, only the cultures that
represent the focus of the infection were included in the analysis. Patients for whom
no follow-up cultures were obtained by the physician within 1 week were excluded
from this analysis. Cox regression analysis was performed to assess the relation
between the fluconazole concentration and the time to culture conversion, thereby
correcting for the leukocyte count and the MIC of the Candida species.
2.2.4 Statistical analysis
Values are expressed as medians with interquartile range (IQR) for continuous
variables and as percentages of the group from which they were derived for cat-
egorical variables. For the univariate analysis, a Spearman correlation coefficient
was calculated to determine correlations between 2 continuous variables. For com-
paring 2 groups, the Mann-Whitney U test was used. Multiple linear regression
was performed with backward analysis, thereby removing nonsignificant variables,
starting with the one with the highest P value. A survival analysis (with time to cul-
ture conversion as possibly censored outcome) was performed using Cox regression
with backward analysis. All statistical analyses were performed using SPSS for Win-
dows, version 20.0 (IBM SPSS, Chicago, Illinois). A P value < 0.05 was considered
statistically significant.
2.3 Results
A total of 112 pediatric patients were evaluated. In 11 patients, fluconazole
trough samples were obtained before steady state was reached and they were there-
fore excluded from the analysis. Two patients were excluded due to incomplete
medical records. As a result, 99 patients were included in the study and their med-
ical records were reviewed. The mean age of the patients was 4.7 years (range,
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0-16 years), and 43 patients (43.4%) were male. The patients‘ characteristics are
summarized in Table 2.1. At least 1 predisposing risk factor was present in all pa-
tients. Cytostatic therapy was used in 29 patients (29.3%), an immunosuppressant
(tacrolimus, mycophenolic acid) in 17 patients (17.2%), and broad-spectrum antibi-
otic therapy in 98 patients (99.0%). Six patients (6.1%) were on dialysis, 81 patients
(81.8%) had a central venous catheter, 29 patients (29.3%) received total parenteral
nutrition, and 54 patients (54.5%) were on mechanical ventilation. Eighty-one pa-
tients (81.8%) had ≥ 3 predisposing risk factors. The causative pathogen was Can-
dida albicans in 74 (74.7%) patients, followed by Candida parapsilosis (6.1%) and Can-
dida tropicalis (4.0%) (Table 2.2). Fluconazole was administered as empirical treat-
ment in 4 patients (4.0%) and for prophylaxis in 1 patient (1.0%).
Overall, fluconazole dosing ranged from 3.0 to 18.9 mg/kg/day. Fluconazole
was dosed according to the SPC in 81 patients (81.8%) (5.5-12.5 mg/kg), 8 patients
(8.1%) received a dose < 5.5 mg/kg, and 10 patients (10.1%) received a dose > 12.5
mg/kg. Seventy patients (70.7%) received fluconazole intravenously and 29 pa-
tients (29.3%) received oral treatment. The fluconazole serum trough concentration
ranged from 2.6 to 46.5 mg/L, an adequate fluconazole trough concentration of >
11 mg/L was achieved in 59 patients (59.6%). The median fluconazole dose (ini-
tial or after dose adjustment) resulting in a trough concentration of > 11 mg/L was
10 mg/kg/day (IQR, 6.3-12 mg/kg/day). Two patients (2.0%) received interacting
comedication with rifampicin, 5 patients (5.1%) received hydrochlorothiazide, and
43 patients (43.4%) received (es-)omeprazole as comedication. None of the patients
received carbamazepine, phenytoin, or barbiturates.
2.3.1 Correlations with fluconazole concentration
Univariate analysis showed a significant positive correlation of the fluconazole
concentration with the fluconazole dose and the serum urea and serum creatinine
concentration and a significant negative correlation with age and weight of the pa-
tients (Table 2.3). The fluconazole trough concentration was significantly lower
in patients with cancer compared with the other patient groups and significantly
higher in premature neonates (vs other patient groups; Figure 2.1 and Table 2.4).
Furthermore, the fluconazole concentration was significantly lower in patients who
received (es-)omeprazole as comedication and did not significantly differ in patients
who stayed in the ICU, patients on dialysis, or patients who received fluconazole
intravenously compared with patients who received oral treatment (Table 2.4). In
the multiple linear regression analysis, variables obtained by the univariate analysis
(age, weight, serum urea and serum creatinine concentration, cancer, SOT, prema-
turity, fluconazole dose, use of (es-)omeprazole) and variables that can theoretically
indicate altered pharmacokinetics (stay in an ICU [22–24] as well as presence of dial-
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Table 2.1: Characteristics of 99 pediatric patients receiving fluconazole. Abbreviations: ALL,
acute lymphoblastic leukemia; AML, acute myeloid leukemia.
Characteristic No. of patients (%)
Sex (male) 43 (43.4%)
Stay in ICU 62 (62.6%)
Age
0-1 months 20 (20.2%)
1-24 months 29 (29.3%)
2-12 years 33 (33.3%)
12-18 years 17 (17.2%)
Underlying condition













a Surgery, other than transplant surgery or surgery related to cancer.
b Other: patients diagnosed with various disorders including pulmonary hypertension, renal insuffi-
ciency, liver failure, meningitis, and pneumonia.
ysis [25]) were included. The multiple linear regression analysis showed a signifi-
cant, independent, and positive association of the fluconazole trough concentration
with the fluconazole dose, weight, and the serum urea concentration, and a sig-
nificant, independent, and negative association with age and cancer as underlying
condition (Table 2.5).
2.3.2 Time to culture conversion
In total, 46 patients had a proven invasive fungal infection, of whom 33 were
included in the survival analysis. Patients excluded from the analysis were 13 pa-
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Table 2.2: Cause and site of infection. Abbreviations: BAL, bronchoalveolar lavage; CVC,
central venous catheter.
Cause/Site of infection No. of patients (%)
Candida species
C. albicans 74 (74.4%)
C. parapsilosis 6 (6.1%)
C. tropicalis 4 (4.0%)
C. lusitaniae 2 (2.0%)
C. glabrataa 2 (2.0%)
C. famata 1 (1.0%)
Yeast not specified 5 (5.1%)
No species isolated 5 (5.1%)
Culture material
Blood 26 (26.3%)
Drain fluidb 15 (15.2%)






a Sensitivity to fluconazole: 1 intermediate, 1 resistant (fluconazole started as empirical treatment).
b Drain fluid: 14 patients abdominal fluid, 1 patient pleural fluid.
Table 2.3: Spearman correlations with the fluconazole trough concentration.
Characteristic Correlation coefficient P value
Age (years) –0.225 0.025
Weight (kg) –0.189 0.061
Fluconazole dose (mg/kg/day) 0.307 0.002
Serum urea (mmol/L) 0.259 0.011
Serum creatinine (µmol/L) 0.275 0.006
tients for whom no follow-up cultures were obtained within 1 week. In 8 of the 33
included patients, negative cultures were never found. In these patients, no further
follow-up cultures were obtained while previous cultures were still positive, or the
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Table 2.4: Fluconazole trough concentration in different patient groups. Fluconazole con-
centration expressed as median with interquartile range. Abbreviations: ICU, intensive care
unit; IV, intravenous.
Characteristic Fluconazole concentration (mg/L) P valueb
Yes No
Sex (male) 12.0 (9.0-17.5) 11.9 (7.1-17.8) 0.745
Route of fluconazole
administration (IV) 12.4 (8.8-17.8) 10.0 (6.0-15.6) 0.138
ICU 12.6 (9.0-18.0) 10.3 (6.8-15.9) 0.146
Dialysis 13.0 (4.7-27.4) 11.9 (7.6-17.6) 0.957
Underlying condition
Solid organ transplant 15.8 (9.6-24.2) 11.4 (7.4-17.0) 0.082
Cancer 7.6 (5.0-13.6) 13.1 (9.7-18.0) 0.002
Surgerya 10.2 (7.1-17.0) 12.0 (7.6-18.0) 0.697
Prematurity 15.7 (12.8-18.1) 11.4 (7.1-17.1) 0.020
Interacting comedication
(Es-)omeprazole 10.3 (6.7-17.1) 13.3 (9.6-18.0) 0.032
Hydrochlorothiazide 12.3 (11.9-22.4) 11.5 (7.3-17.5) 0.209
Rifampicin 13.3 (11.8-13.3) 11.9 (7.5-17.7) 0.757
a Surgery, other than transplant surgery or surgery related to cancer.
b Determined by using the Mann-Whitney U test.
Table 2.5: Multiple linear regression model of factors that are significantly correlated with the
fluconazole trough concentration. Abbreviations: CI, confidence interval. R2 of the model =
0.443, R2 change = –0.007, compared with the model with all variables included.
Factor Effect 95% CI P value
Serum creatinine (µmol/L) 0.043 –0.006 to 0.092 0.085
Fluconazole dose (mg/kg/day) 0.805 0.403 to 1.208 < 0.001
Age (years) –0.899 –1.502 to –0.296 0.004
Weight (kg) 0.249 0.063 to 0.436 0.009
Serum urea (mmol/L) 0.637 0.224 to 1.050 0.003
Cancer –5.019 –8.334 to –1.704 0.003
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Figure 2.1: Median fluconazole trough concentration for different patient groups. Median
box plot with interval from the 10th percentile to the 90th percentile of the fluconazole trough
concentration and median fluconazole dose (mg/kg/day) for patients with different underly-
ing conditions. The dotted line represents a trough concentration of fluconazole of 11 mg/L,
which is considered to be representative of an area under the concentration-time curve of 400
mg*h/L. Abbreviations: SOT, solid organ transplant. Surgery, other than transplant surgery
or surgery related to cancer. Other: patients diagnosed with various disorders including pul-
monary hypertension, renal insufficiency, liver failure, meningitis and pneumonia.
patient died before cultures became negative. These 8 patients were included as
censored data in the analysis. The median number of follow-up cultures from the
start of fluconazole until the first negative culture was 1 culture per 2 days (IQR, 1
culture per 5 days-1 culture per day) for a median period of 5 days (IQR, 3-11 days)
for the patients included in the survival analysis. The fluconazole trough concentra-
tion was significantly associated with the time to culture conversion, when corrected
for the leukocyte count. A higher fluconazole concentration was associated with a
shorter time to culture conversion (hazard ratio [HR] = 1.076 [95% confidence inter-
val {CI}, 1.017-1.138]; P = 0.011). Because the HR is > 1, an increase in fluconazole
concentration reduces the time to a negative culture. In 21 of the 33 patients, the
MIC of the Candida species was available. When corrected for the leukocyte count
and the Candida MICs, a HR of 1.052 (95% CI, 1.003-1.103; P = 0.036) was found.
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Fifteen patients deceased during the hospitalisation period in which fluconazole
was administered. Five of these 15 patients had a proven IC; however, this number
was too small to perform statistical analysis.
2.4 Discussion
Pediatric cancer patients had a lower fluconazole serum concentration compared
with the other patient groups, corrected for age, weight, renal function, and the flu-
conazole dose. Furthermore, the fluconazole concentration was < 11 mg/L and
hence subtherapeutic in 40% of all pediatric patients, and the fluconazole concen-
tration was negatively correlated with the time to culture conversion.
Multiple linear regression analysis showed that the fluconazole concentration
was significantly associated with the fluconazole dose. A higher maintenance dose
of fluconazole can be administered to achieve a therapeutic serum concentration
of fluconazole. In 2012, our hospital guideline was revised in accordance with the
IDSA and ESCMID guideline and a fluconazole dose of 12 mg/kg/day was recom-
mended, instead of the 6-12 mg/kg/day advised in the SPC of fluconazole. This
12 mg/kg/day dosing regimen is most likely a better approach to achieve a suffi-
cient fluconazole exposure. Besides the fluconazole dose, the age and weight of the
patient were significantly associated with the fluconazole concentration. Develop-
mental changes in renal function, and to a lesser extent, the gastrointestinal tract
and volume of distribution can contribute to the varying fluconazole concentration
with age [32,33]. Even though the fluconazole dose was corrected for weight, heav-
ier patients generally had a higher fluconazole concentration. Because fluconazole
is a highly hydrophilic drug and is administered based on total body weight, pa-
tients who are overweight receive a proportionally higher fluconazole dose. As ex-
pected, the serum urea concentration and the serum creatinine concentration were
both correlated with the fluconazole concentration. Finally, patients with cancer
had a significantly lower fluconazole concentration. Because the renal function was
included in the analysis, the observed lower fluconazole concentration in cancer
patients is most likely the result of an enlarged volume of distribution. The large
volume of distribution is probably the result of a shift in body water reservoirs. The
shift in body water can be the result of the underlying illness or treatment with
chemotherapy [26, 33]. The administration of hyper-hydration during chemother-
apy can also lead to an enlarged volume of distribution, although most patients did
not receive hyper-hydration at the time the fluconazole trough levels were obtained.
Of the patients with cancer, 18 of the 28 patients received fluconazole through intra-
venous treatment, which makes the presence of vomiting or diarrhoea not likely as
a cause of the low fluconazole concentration in this patient group. Furthermore,
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low drug concentrations in cancer patients are also seen with antimicrobial agents
such as aminoglycosides, vancomycin, and teicoplanin, which are also highly hy-
drophilic drugs, and higher doses of these drugs are recommended in cancer pa-
tients [26, 34, 35]. Hence, this patient group is currently underdosed and a higher
fluconazole dose than currently recommended is required to achieve an adequate
drug exposure. A prospective dose-finding study of fluconazole in pediatric cancer
patients should be carried out to determine a more appropriate fluconazole dose for
this patient group.
A limitation of this study is its retrospective nature, possibly introducing se-
lection bias and suffering from incomplete data in the medical records. Because
fluconazole concentrations were measured routinely in our hospital in critically ill
pediatric patients, and not just when efficacy or safety were in question, we expect
selection bias to be limited. In addition, we used strict criteria for completeness of
the data for analysis with respect to clinically relevant endpoints. Furthermore, MIC
values of the Candida species were only available for patients with positive blood
cultures. A significant association between the fluconazole concentration and cul-
ture conversion was still found when corrected for the MIC of the organism. How-
ever, the number of patients was small, the MIC values of the patient group showed
a narrow distribution, and were all below the susceptibility breakpoint. When the
MIC is < 8 mg/L (CLSI breakpoint), an AUC of fluconazole < 400 mg*h/L is suffi-
cient to reach an AUC/MIC of 50. This emphasizes the importance of susceptibility
testing to prevent unnecessary dose increase. However, in case of empirical treat-
ment, the MIC of the Candida species is not known at the start of the fluconazole
treatment. Then, the strategy would be to acquire at least adequate exposure to
cover Candida species with a MIC of 8 mg/L. Rapid target attainment by increas-
ing the dose of fluconazole to reach an AUC of > 400 mg*h/L is not likely to cause
adverse drug reactions as fluconazole has a good safety profile [21].
Based on the results of our study, we believe that the current opinion of TDM
not being of added value for fluconazole should be reevaluated. TDM can help
to ensure timely target attainment of fluconazole in critically ill pediatric patients
who are at risk of underexposure, in particular in cancer patients. Preferably, new
dosing recommendations should be developed for these patients, reducing the need
for TDM. However, TDM of fluconazole is of potential added value in critically ill
children who do not respond adequately to the fluconazole therapy. Because the
mortality of IC in pediatric patients is still up to 29% with antifungal treatment,
TDM can help to optimize the treatment with fluconazole. With the use of LC-
MS/MS analysis, a sample volume of only 10 µL serum or plasma is required for
the analysis. From the sample obtained for clinical chemistry, this volume can be
easily spared to perform a fluconazole concentration measurement.
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2.5 Conclusion
In conclusion, the fluconazole concentration was insufficient in pediatric cancer
patients compared with other patient groups, and a higher fluconazole dose than
currently recommended is required to achieve adequate drug exposure in this pa-
tient group. Furthermore, the fluconazole concentration was negatively correlated
with the time to culture conversion. TDM can be a valuable tool to detect possi-
ble fluconazole underexposure in critically ill pediatric patients failing to respond
to therapy. Subsequently, dose adjustment of fluconazole to achieve therapeutic flu-
conazole concentrations can lead to an increased efficacy of the antifungal treatment
and a better outcome of IC.
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Chapter 3
Clinical
validation of the analysis of fluconazole in oral
fluid in hospitalized children
Abstract
Fluconazole is a first-line antifungal agent for the treatment and prophylaxis of invasive
candidiasis in pediatric patients. Pediatric patients are at risk of suboptimal drug ex-
posure, due to developmental changes in gastrointestinal and renal function, metabolic
capacity, and volume of distribution. Therapeutic drug monitoring (TDM) can therefore
be useful to prevent underexposure of fluconazole in children and infants. Children, how-
ever, often fear needles and can have difficult vascular access. The purpose of this study
was to develop and clinically validate a method of analysis to determine fluconazole in
oral fluid in pediatric patients. Twenty-one paired serum and oral fluid samples were
obtained from 19 patients and were analyzed using a validated liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method after cross-validation between serum
and oral fluid. The results were within accepted ranges for accuracy and precision, and
samples were stable at room temperature for at least 17 days. A Pearson correlation test
for the fluconazole concentrations in serum and oral fluid showed a correlation coefficient
of 0.960 (P < 0.01). The mean oral fluid-to-serum concentration ratio was 0.99 (95%
confidence interval [CI], 0.88 to 1.10) with Bland-Altman analysis. In conclusion, an
oral fluid method of analysis was successfully developed and clinically validated for flu-
conazole in pediatric patients and can be a noninvasive, painless alternative to perform
TDM of fluconazole when blood sampling is not possible or desirable. When patients re-
ceive prolonged courses of antifungal treatment and use fluconazole at home, this method
of analysis can extend the possibilities of TDM for patients at home.
3.1 Introduction
Fluconazole was introduced in 1990 and is still a first-line antifungal agent for thetreatment and prophylaxis of invasive candidiasis in children and infants [1,2].
The bioavailability of orally administered fluconazole is over 90%, and flucona-
zole has excellent penetration in tissue and body fluids [3, 4]. The pharmacoki-
netic/pharmacodynamic parameter that best predicts the outcome of the flucona-
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zole treatment is the area under the concentration-time curve over 24 h in steady
state divided by the minimum inhibitory concentration (AUC/MIC) [5, 6]. To en-
sure an AUC/MIC of ≥ 50, which corresponds to a favourable outcome, an AUC of
≥ 400 mg*h/L is required for Candida species with a MIC breakpoint ≤ 8 mg/L [7–
10]. Routine therapeutic drug monitoring (TDM) of fluconazole is currently not
advised due to its high bioavailability, linear dose-concentration relationship, and
good safety profile [1,11,12]. However, children and infants are at risk of suboptimal
drug exposure, due to developmental changes in the gastrointestinal and renal func-
tion, metabolic capacity, and volume of distribution [13]. A previous study showed
that the serum fluconazole concentration was correlated with the age, weight, and
renal function of critically ill pediatric patients and that the fluconazole exposure
was not sufficient in pediatric cancer patients [14]. TDM of fluconazole can therefore
be useful to prevent possible underexposure in critically ill pediatric patients [14,15].
Since obtaining a blood sample from children is often more complicated than for
adults and children often fear needles, oral fluid sampling can be a noninvasive,
painless alternative to plasma or serum [16]. Previous studies showed a mean ra-
tio of the saliva drug concentration to the plasma drug concentration of approxi-
mately 1 for fluconazole in healthy volunteers [3,17,18]. However, in another study,
a saliva-to-plasma concentration ratio of 0.4 was found [19]. A median saliva-to-
plasma ratio of 1.1 to 1.3 was seen in adult patients with HIV or AIDS [20, 21] and
a mean ratio of 1.4 in adult cancer patients who underwent radiotherapy [22]. The
correlation between fluconazole in oral fluid and in plasma or serum has not yet
been studied in children. The purpose of this study was to develop and clinically
validate a method of analysis of fluconazole in oral fluid in hospitalized children
with an (invasive) Candida infection and to evaluate the fluconazole exposure in
these children.
3.2 Materials and Methods
3.2.1 Study design
This prospective observational study was conducted in the 150-bed pediatric de-
partment of the University Medical Center Groningen, Groningen, the Netherlands,
from July 2007 to March 2014. Patients were eligible for inclusion if the following
criteria were met: (1) age, 0 to 18 years; (2) admission to a pediatric ward or pe-
diatric/neonatal intensive care unit (ICU); (3) oral or intravenous treatment with
fluconazole; and (4) scheduled routine TDM of fluconazole in serum. Children from
whom it was impossible to get oral fluid or who had serious mucositis of their oral
cavity or oral thrush were excluded from the study. The study protocol was ap-
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proved by the local medical ethics committee (institutional review board protocol
no. 2007.198). For patients less than 12 years of age, written informed consent was
given by the parents, and for patients over 12 years of age, the patient and parents
were both asked to give informed consent. The study population was also included
in a retrospective study of fluconazole exposure by van der Elst et al. [14].
Routine serum and oral fluid trough samples were obtained pairwise before ad-
ministration of fluconazole. Fluconazole samples were eligible for evaluation when
obtained at steady state, which is after 2 days when a loading dose has been given
or after 5 days without a loading dose [10, 23]. Serum was obtained by centrifug-
ing the blood samples, and the serum was directly analyzed or stored at –20◦C
until analysis. Only the unbound fraction of fluconazole is present in oral fluid.
Since the protein binding of fluconazole is only 11 to 12% [18, 20], the total flucona-
zole concentration was determined in serum. Oral fluid samples were obtained
by chewing/sucking for 1 minute on a small cotton roll (Salivette, without prepa-
ration; Sarstedt, Leicester, United Kingdom). If the patient was unable to chew,
the oral fluid samples were obtained through suction of the oral fluid with a rou-
tine suction device. Oral fluid samples were directly centrifuged and stored at –
20◦C until analysis. Demographic and clinical data were collected through review
of the medical records and included age, sex, weight, renal function (serum urea
and serum creatinine concentration), underlying condition, stay in an ICU, and the
Candida species. Medical data were collected on the fluconazole dose (mg/kg of
body weight/day) and route of administration, fluconazole trough concentration,
and duration of treatment.
3.2.2 Oral fluid method validation
Fluconazole serum and oral fluid samples were analyzed using a previously vali-
dated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method [24].
The analytical method was validated in accordance with the Guidance for Industry,
Bioanalytical Method Validation of the Food and Drug Administration [25]. Cross-
validation between serum and oral fluid was performed by comparing calibration
samples of pooled serum and pooled oral fluid. The lower limit of quantification
(LOQ) was 0.5 µg/ml for both the serum and oral fluid assays. The linearity of the
standard curve was assessed with 1/x2 weighting over a concentration range of 0.5
to 50.0 µg/ml. Accuracy and precision were evaluated for quality control samples
at concentrations of 0.5, 1.0, 2.5, 5.0, 10.0, 20.0, 40.0, and 50.0 µg/ml in triplicate.
Stability was assessed by storing oral fluid samples with fluconazole concentrations
of 1.0 µg/ml (low), 20.0 µg/ml (medium), and 40.0 µg/ml (high) at room temper-
ature (20◦C) for 1, 3, 5, and 17 days. For the determination of the recovery of flu-
conazole from the cotton rolls, 1.5 ml spiked oral fluid at low, medium, and high
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concentrations was applied to the Salivette. Afterwards, the Salivettes were cen-
trifuged, and the extracts were compared to blank oral fluid subsequently spiked at
low, medium, and high concentrations. The recovery was determined immediately
after preparation of the Salivettes and after storing the Salivettes for 2 and 6 days
at room temperature (20◦C). The analysis was clinically validated by comparing the
fluconazole concentrations in paired serum and oral fluid samples from patients.
Furthermore, the percentage of patients with a fluconazole trough concentration of
< 11 µg/ml [10, 14, 23] was determined.
3.2.3 Statistical analysis
In the analytical method validation, bias was defined as the difference between
the analytical result and the nominal concentration, expressed as a percentage. The
oral fluid analysis was validated by comparing the serum fluconazole concentration
with the concentration of fluconazole in oral fluid using Passing-Bablok regression
and Bland-Altman analysis (with Analyse-it 2.20 software). Furthermore, a Pearson
correlation coefficient was calculated to determine the correlation between the con-
centrations in serum and oral fluid. Additionally, a leave-one-out cross-validation
was performed to validate the predictive performance of a linear regression model
used to predict serum concentrations based on oral fluid concentrations. In this
model, the serum fluconazole concentration was set as the dependent variable and
the oral fluid fluconazole concentration as the independent variable. The model was
refitted n times (with n the total number of observations) while leaving out a single
observation t, so that a prediction could be derived for the left-out observation based
on all other observations. The error for observation t was then defined as the dif-
ference between the observed and predicted serum fluconazole concentrations, as
follows: Y obst − Y predt . In order to determine the performance of the linear regres-
sion model, the root mean square error (RMSE) was calculated using the following
equation:
RMSE =
√√√√∑nt=1 (Y obst − Y predt )2
n
(3.1)
In regard to patients, values are expressed as medians with interquartile range
(IQR) for continuous variables and as percentages of the group from which they
were derived for categorical variables. A Spearman correlation coefficient was cal-
culated to determine correlations between two continuous variables. To compare
two groups, the Mann-Whitney U test was used. Statistical analyses were per-
formed using SPSS for Windows, version 20.0 (IBM SPSS, Chicago, IL). A P value of
< 0.05 was considered statistically significant.
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Table 3.1: Characteristics of 19 children and infants receiving fluconazole.
Characteristic No. of patients (%)
Gender (male) 9 (47.4%)
Age
0-1 months 2 (10.5%)
1-24 months 8 (42.1%)
2-12 years 6 (31.6%)
12-18 years 3 (15.8%)
Underlying condition





Stay in intensive care unit 11 (57.9%)
a 1 patient was diagnosed with cardiac and respiratory insufficiency, 1 patient with liver failure, and
1 patient with spina bifida.
3.3 Results
A total of 19 patients were included in the study, and their medical records were
reviewed. The mean age of the patients was 4.6 years (range, 22 days to 16 years),
and 9 patients (47.4%) were male. The patients‘ characteristics are summarized in
Table 3.1. The causative pathogen was Candida albicans in 16 patients (84.2%), C.
parapsilosis in 1 patient (5.3%), C. krusei in 1 patient (5.3%), and not specified in 1
patient (5.3%). The median fluconazole dose was 9.4 mg/kg/day (IQR, 6.4 to 10.4
mg/kg/day), and the median duration of the fluconazole treatment was 31 days
(IQR, 18 to 61 days). Thirteen patients (68.4%) received fluconazole intravenously,
and 6 patients (31.6%) received oral treatment. The fluconazole serum trough con-
centrations ranged from 2.8 to 37.5 µg/ml.
3.3.1 Analytical method validation
The serum and oral fluid analytical method showed good linearity over the flu-
conazole concentration range. The regression equations and correlation coefficients
were as follows: 0.00195 + 0.0274 x response and r2 = 0.998 for serum and –0.000461
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+ 0.0265 x response and r2 = 0.997 for oral fluid. The mean measured concentra-
tions were between 93.8% and 102.7% of the nominal concentration for serum and
between 96.6% and 107.4% for oral fluid. The calibration curves were analyzed in
triplicate, with the coefficients of variation between 1.2% and 5.9% for serum and
between 1.4% and 5.4% for oral fluid, well within the required limit of < 15% for
the whole concentration range. Serum samples were stable at room temperature
(20◦C) for 7 days, with a bias of 2.3% for the low, 7.6% for the medium, and 5.6%
for the high concentrations (24). Oral fluid samples were stable at room tempera-
ture (20◦C) for 1, 3, 5, and 17 days, with a bias of 3.5% to 12.9% for the low, 2.8%
to 6.1% for the medium, and –0.6% to 5.7% for the high concentrations. The recov-
ery of the fluconazole extraction from the cotton rolls was between 93.5% and 97.8%
for the freshly prepared Salivettes and between 97.3% and 104.8% after storing the
Salivettes at room temperature (20◦C) for 2 and 6 days and was well within the
required limit of < 15%.
3.3.2 Clinical validation
Twenty-one paired serum and oral fluid samples from 19 patients were included
in the clinical validation of the oral fluid analysis. A Pearson correlation test showed
a correlation coefficient of 0.960 (P < 0.01) for the fluconazole concentrations in
serum and oral fluid. The unadjusted median of the oral fluid-to-serum ratio was
1.00 (range, 0.59 to 1.46). Passing-Bablok regression between the serum and oral
fluid drug concentrations showed a proportional bias of 0.87 (95% confidence in-
terval [CI], 0.69 to 0.98) and a constant bias of 1.19 (95% CI, 0.44 to 2.92) (Fig. 3.1).
With Bland-Altman analysis, the mean oral fluid-to-serum drug concentration ra-
tio versus the mean concentration in oral fluid and serum was 0.99 (95% CI, 0.88 to
1.10). Twenty out of 21 values were within the limits of agreement of 95% (Fig. 3.2).
Using a leave-one-out cross-validation analysis, the standard deviation of the error
in the predictive linear regression model was found to be 3.1 µg/ml. The oral fluid-
to-serum drug concentration ratio did not significantly differ in patients receiving
oral treatment versus intravenous treatment (P = 0.791). No significant correlation
was found between the oral fluid-to-serum drug concentration ratio and the age (P
= 0.316) or weight (P = 0.266) of the patient, the renal function (P = 0.743 for urea
and P = 0.186 for the creatinine concentration), or the fluconazole dose (P = 0.636).
Ten patients (52.6%) had a serum fluconazole concentration of < 11 µg/ml, which is
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Figure 3.1: Scatter plot (n=21) with Passing-Bablok regression between serum and oral fluid
concentrations. The regression line of fluconazole is presented as a solid line and has a slope
of 0.87 (95% CI, 0.69 to 0.98) and an intercept of 1.19 (95% CI, 0.44 to 2.92).
3.4 Discussion
An oral fluid analysis for fluconazole was developed and clinically validated in
pediatric patients. The fluconazole concentration in oral fluid was in good agree-
ment with the serum fluconazole concentration. The mean oral fluid-to-serum drug
concentration ratio was 1, which corresponds to the ratio of 1 reported in the Sum-
mary of Product Characteristics of fluconazole [18] and in studies in healthy volun-
teers [3,17]. Fluconazole has a low protein binding of 11% to 12% and is largely non-
ionized under physiological conditions, which makes fluconazole easily penetrate
in oral fluid [18, 20]. In the high-concentration area (> 30 µg/ml), the concentration
in oral fluid was lower than the concentration in serum, which possibly indicates
saturation of the amount of fluconazole in the oral fluid. It is possible that flu-
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Figure 3.2: Bland-Altman plot of the oral fluid-to-serum drug concentration ratio versus the
mean concentration in oral fluid and serum. The bias is presented as a solid line, and the 95%
limits of agreement are presented as dashed lines. The mean bias is 0.99 (95% CI, 0.88 to 1.10),
and the lower and upper 95% limits of agreement are 0.53 (95% CI, 0.34 to 0.72) and 1.45 (95%
CI, 1.27 to 1.64), respectively.
transport mechanism [20]. However, there were only 2 patients with a serum trough
concentration of > 30 µg/ml, and previous reports studied fluconazole trough con-
centrations only up to 10 µg/ml [17, 19, 20, 22, 26].
The overall bias between the fluconazole concentrations in oral fluid and serum
found with Bland-Altman analysis was low. However, in the low-concentration
area, a larger bias was seen in the in oral fluid-to-serum ratio with Bland-Altman
analysis. Furthermore, the standard deviation of the error in the predictive linear
regression model was 3.1 µg/ml. When increasing the fluconazole dose in case of
underexposure based on the oral fluid drug concentration, this standard deviation
must be taken into account, especially when the measured concentration is ranged
around the target concentration. A slightly higher fluconazole trough concentration
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can be pursued to ensure the exposure is adequate. This higher fluconazole concen-
tration is not likely to cause adverse drug reactions, since fluconazole has a good
safety profile and is well tolerated in pediatric patients at higher doses [12]. In case
the MIC of the Candida species is known, the fluconazole dose can be adjusted to
achieve the required exposure and to prevent unnecessary dose increase. TDM of
fluconazole revealed a fluconazole trough concentration of < 11 µg/ml in 52.6% of
the pediatric patients. Hence, TDM of fluconazole can be useful to detect possible
underexposure in children and infants.
In our hospital, only trough concentrations of fluconazole were measured and
included in the clinical validation. The oral fluid-to-serum concentration ratio of 1
that was found in this study can therefore be applied only to fluconazole trough con-
centrations. A trough concentration is probably most convenient to obtain and will
give no drug contamination when fluconazole is administered orally. Furthermore,
oral fluid was collected by chewing/sucking on a small cotton roll (Salivette) or by
a routine suction device when the patient was not able to chew. Collection devices
other than the Salivette have not been clinically validated in our study. Research has
shown that Salivette collection devices achieve good recovery for most drugs, and
they were found to be very practical and convenient for the user [27]. In contrast
with full-term infants, the collection of oral fluid from premature neonates was dif-
ficult, since these patients produce very little oral fluid. Oral fluid sampling is there-
fore not suitable for premature neonates. In some other cases, blood sampling may
also be preferred over oral fluid sampling, for example, when other laboratory tests
are ordered along with the fluconazole measurement. Furthermore, in patients with
severe mucositis or other damage to or inflammation of the oral mucosa/salivary
glands and in patients where oral fluid production is reduced (e.g., when treated
with anticholinergic comedication), blood sampling is preferred [16].
Based on the result of our study, TDM of fluconazole in oral fluid can be a non-
invasive, painless alternative to serum in children who fear needles or who have
difficult vascular access. Oral fluid sampling is preferred over blood sampling by
the majority of patients and their parents [16]. Besides, oral fluid sampling can re-
duce costs due to the lower level of training of personnel, less time needed for oral
fluid sampling, and lower costs of materials used for oral fluid sampling [16]. When
patients receive prolonged courses of antifungal treatment and use fluconazole at
home, oral fluid sampling by the parents or the patient can extend the possibilities
of TDM for patients at home. Samples do not have to be obtained solely during
office hours and can be shipped by mail, thereby avoiding trips to the hospital, and
the biohazard risk when shipping oral fluid samples is low. Furthermore, the physi-
cian already has the results of the analysis before the consultation or can give advice
to adjust the dose over the telephone.
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3.5 Conclusion
In conclusion, an oral fluid method of analysis was successfully developed and
clinically validated for fluconazole in hospitalized children and infants and can be a
noninvasive, painless alternative to perform TDM of fluconazole when blood sam-
pling is not possible or desirable.
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Chapter 4
Subtherapeutic posaconazole exposure and the
relation with treatment outcome in patients at
risk of and with invasive fungal disease
Abstract
Background: The posaconazole exposure appears to be subtherapeutic in a part of the
patients with invasive fungal disease. Due to the pharmacokinetic variability of posaco-
nazole, therapeutic drug monitoring may help to optimize the efficacy of the antifungal
treatment.
Materials & Methods: A retrospective study of patients treated with posaconazole
from January 2008 to April 2014 and for whom posaconazole serum concentrations were
available was conducted. Risk factors for underexposure of posaconazole were detected
and the relation between the posaconazole exposure and the treatment outcome according
to the EORTC criteria was assessed.
Results: Seventy patients met the inclusion criteria, 45 patients received posaconazole
as treatment and 25 patients received posaconazole as prophylaxis. The posaconazole
serum concentration was < 1.25 mg/L in 44.4% of the patients receiving treatment and
< 0.7 mg/L in 40.0% of the patients receiving prophylaxis. Multiple linear regression
analysis showed a significant, independent, and negative association of the posaconazole
serum trough concentration with a lack of enteral nutrition (P < 0.001), vomiting (P
= 0.035), the use of a proton-pump inhibitor or H2-receptor antagonist (P < 0.001), a
liquid diet (P = 0.002), concomitant chemotherapy (P = 0.004), and a posaconazole dose
frequency of 2 times daily (P = 0.015). A higher posaconazole concentration was as-
sociated with a better treatment outcome (odds ratio = 22.22 [95% confidence interval,
3.40-145.33]; P = 0.001).
Conclusions: The posaconazole exposure is not sufficient in over 40% of the patients at
risk of or with invasive fungal disease and the posaconazole exposure is positively corre-
lated with a successful treatment outcome. Therapeutic drug monitoring of posaconazole




nvasive aspergillosis (IA) is the leading cause of infection-related death in patients
with acute leukemia and in hematopoietic stem cell transplant (HSCT) recipi-
ents [1]. Risk factors for IA are prolonged neutropenia, immunosuppression after
stem cell or solid organ transplantation, AIDS, chronic granulomatous disease, and
pre-existing structural lung disease [1, 2]. A crude mortality up to 49% is seen and
IA is associated with an increase in length of hospital stay and increased costs [2–5].
The guideline of the Infectious Diseases Society of America for the treatment of as-
pergillosis recommends the use of posaconazole for prophylaxis against IA in neu-
tropenic patients with acute myelogenous leukemia or myelodysplastic syndrome
and in HSCT recipients, and as an alternative choice for salvage therapy of IA [2].
The recommended posaconazole dose is 200 mg 3 times daily for prophylaxis and
200 mg 4 times daily for the treatment of IA [6].
Various pathophysiological changes in severely ill patients, such as cancer pa-
tients, can affect the pharmacokinetics of antimicrobial agents [7, 8]. Furthermore,
drug absorption issues (food, gastric pH) and drug-drug interactions contribute to
the intra- and interindividual patient variability of the pharmacokinetics of posaco-
nazole [2, 9–15]. Data from earlier studies with posaconazole showed that average
steady state concentrations of at least 0.7 mg/L for prophylaxis and 1.25 mg/L for
treatment were associated with a better outcome [16–18]. However, these target con-
centrations are not attained in a high proportion of patients with hematologic malig-
nancies, resulting in suboptimal drug exposure [19–22]. Therapeutic drug monitor-
ing (TDM) of posaconazole may play an important role in optimizing drug exposure
and hence the efficacy of the antifungal treatment [2, 23]. The purpose of this study
was to determine risk factors for underexposure of posaconazole and to assess the
relation between the posaconazole exposure and the treatment outcome in patients
with invasive fungal disease (IFD).
4.2 Materials and methods
4.2.1 Study design and data collection
This retrospective study was conducted at the University Medical Center Gronin-
gen, a 1339-bed university hospital in the Netherlands. TDM of antimicrobial drugs
is routinely performed in critically ill patients in our hospital. Patients were eligible
for inclusion if the following criteria were met: (1) age ≥ 17 years, (2) admission be-
tween 1 January 2008 and 31 March 2014, (3) treatment with posaconazole, and (4) at
least one steady state serum trough concentration of posaconazole available (at least
7 days after the start of the posaconazole treatment and at least 7 days on the same
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dose regimen). The study was evaluated by the local ethics committee (Institutional
Review Board protocol no. 2013-491) and was approved in accordance with Dutch
legislation due to its retrospective nature.
Data were collected through review of the medical records using a standard-
ized case report form. Demographic and clinical data were collected including age,
sex, body mass index (BMI), underlying condition, leukocyte count, C-reactive pro-
tein (CRP), hepatic function (γ-GT, ALAT, bilirubin, and albumin concentration),
presence of a HSCT, vomiting (scored positive if present for ≥ 2 days), diarrhea
(for ≥ 2 days), chemotherapy during treatment with posaconazole, and the food
intake of the patient. Furthermore, it was determined whether posaconazole was
used for prophylaxis or salvage treatment. In case posaconazole was used as treat-
ment, the IFD was classified as proven, probable, or possible according to the 2008
definition of IFD from the European Organization for Research and Treatment of
Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus
Group [24]. Besides, data were collected on the posaconazole dose and frequency
per day, route of administration (oral/nasogastric tube), posaconazole serum trough
concentration, duration of posaconazole treatment, and interacting comedication.
4.2.2 Posaconazole exposure
To evaluate the exposure, posaconazole serum trough concentrations were de-
termined using a validated liquid chromatography-tandem mass spectrometry as-
say [25] and externally confirmed by proficiency testing [26]. A trough concentra-
tion of posaconazole ≥ 0.7 mg/L was considered adequate for prophylaxis and a
trough concentration ≥ 1.2 mg/L as adequate for the treatment of IFD [16–19]. To
determine risk factors for underexposure of posaconazole, we assessed the asso-
ciation of the first posaconazole trough concentration at steady state with factors
that could possibly influence the pharmacokinetics of posaconazole, including the
patients‘ age, BMI, hepatic function, and the CRP concentration [6, 27]. Besides,
we compared the posaconazole concentration between patient groups with differ-
ent gender, food intake, posaconazole dosing schedules, the occurrence of vomiting
and diarrhea, concomitant treatment with chemotherapy, and the use of interact-
ing comedication (proton-pump inhibitors (PPI), H2-receptor antagonists, metoclo-
pramide [10, 14, 28]). Finally, we performed a multiple linear regression analysis
to assess the relation between the posaconazole concentration and the explanatory
variables.
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4.2.3 Treatment outcome and treatment optimization strategies
For patients who received posaconazole as prophylaxis, the presence of a break-
through fungal infection was noted. For patients who received posaconazole as cu-
rative treatment, the outcome was classified as complete, partial, or stable response,
progression of the disease, or death, according to the 2008 definition of responses
to therapy and study outcomes in clinical trials of IFD from the MSC and EORTC
Consensus Criteria [29], at the end of treatment. A complete or partial response was
defined as a successful treatment and progression of the disease or death as treat-
ment failure. An ordinal regression analysis was performed to assess the relation
between the posaconazole exposure and the treatment outcome (with (1) success-
ful treatment, (2) stable treatment, and (3) treatment failure) correcting for variables
that may influence the treatment outcome, including the age and the immune status
of the patient.
In patients with a subtherapeutic posaconazole concentration, we evaluated sev-
eral strategies that were applied to increase the posaconazole concentration: (1)
administration of posaconazole with an acidic beverage, (2) discontinuation of the
PPI/H2-receptor antagonist, (3) discontinuation of total parenteral nutrition (TPN)
and start administering posaconazole with food, and (4) increase of the posacona-
zole dose.
4.2.4 Statistical analysis
For the univariate analysis, a Spearman correlation coefficient was calculated to
determine correlations between two continuous variables. For comparing 2 or more
groups, the Mann-Whitney U test and Kruskal-Wallis test were used. To assess the
relationship between the posaconazole exposure and several explanatory variables,
variables with a P-value of < 0.10 from the univariate analysis and variables that
theoretically can influence the posaconazole exposure were included in the multi-
ple linear regression analysis. Multiple linear regression analysis, with the posaco-
nazole concentration as log-transformed dependent variable, was performed with
backward analysis, thereby removing non-significant variables, starting with the
one with the highest P value. After performing multiple linear regression, the resid-
uals were checked. For the determination of the relationship of the posaconazole
exposure with the treatment outcome in patients receiving curative treatment, an
ordinal regression analysis was performed. All statistical analyses were performed
using SPSS for Windows, version 22.0 (IBM SPSS, Chicago, Illinois). A P value <
0.05 was considered statistically significant.
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Table 4.1: Patient characteristics (n=70) and indication for antifungal therapy with posacona-
zole. Abbreviations: BMI, body mass index; IFD, invasive fungal disease; IQR, interquartile
range.
Characteristic No. of patients (%)
Gender (male) 43 (61.4%)
Age (years, median, IQR) 51 (38-59)
BMI (kg/m2, median, IQR) 23.4 (21.1-26.8)
Underlying condition
Hematological malignancies 55 (78.6%)
Acute myeloid leukemia 23 (32.9%)
Acute lymphoblastic leukemia 9 (12.9%)
Non-Hodgkin lymphoma 6 (8.6%)
Hodgkin lymphoma 1 (1.4%)
Chronic myelogenous leukemia 3 (4.3%)
Chronic lymphocytic leukemia 4 (5.7%)
Multiple myeloma 3 (4.3%)
Myelodysplastic syndrome 6 (8.6%)
Solid organ transplantationa 8 (11.4%)
Other underlying conditionb 7 (10.0%)
Posaconazole prophylaxis 25 (35.7%)
Posaconazole treatment 45 (64.3%)
Proven IFD 22 (31.4%)
Aspergillus fumigatus 11 (15.7%)
Aspergillus flavus 1 (1.4%)
Candida non-albicans 3 (4.3%)
Scedosporiumc 2 (2.9%)
Rhizomucord 2 (2.9%)
Absidia corymbifera 2 (2.9%)
Hormographiella aspergillata 1 (1.4%)
Probable IFD 7 (10.0%)
Possible IFD 16 (22.9%)
a 5 patients lung transplantation, 3 patients liver transplantation.
b 1 Cystic fibrosis, 1 HIV, 1 aplastic anemia, 1 myelofibrosis, 1 hemoptysis, 1 thorax trauma, 1
common variable immunodeficiency.
c 1 Scedosporium prolificans, 1 Scedosporium apiospermum.
d 1 Rhizomucor pusillus, 1 Rhizomucor not specified.
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4.3 Results
A total of 81 patients received posaconazole. In 11 patients, TDM of posacona-
zole was not performed or trough samples were obtained before steady state was
reached and they were excluded from the analysis. As a result, 70 patients met the
inclusion criteria and their medical records were reviewed. The median age of the
patients was 51 years (interquartile range [IQR], 38-59 years), and the most com-
mon underlying condition was a hematologic malignancy (78.6%). The patients‘
characteristics are summarized in Table 4.1. Twenty-eight patients (40.0%) received
a HSCT, and 22 patients (31.4%) received chemotherapy during treatment with po-
saconazole. Six patients (8.6%) received TPN, 17 patients (24.3%) had a nasogas-
tric tube or a liquid diet, and 47 patients (67.1%) had a normal diet. Twenty-five
patients (35.7%) received posaconazole for prophylaxis, and 45 patients (64.3%) re-
ceived posaconazole as treatment (Table 4.1). In patients receiving posaconazole for
prophylaxis, the posaconazole dose was 600 mg/day in 21 patients (84.0%) and 800
mg/day in 4 patients (16.0%). The median posaconazole serum concentration was
0.9 mg/L (IQR, 0.5-1.7 mg/L) and in 15 patients (60.0%) an adequate posaconazole
trough concentration of ≥ 0.7 mg/L was achieved. For the patients in the treatment
group, the posaconazole dose was 800 mg/day in 36 patients (80.0%), 600 mg/day
in 8 patients (17.8%), and 1 patient received a dose of 960 mg/day. The median po-
saconazole serum concentration was 1.2 mg/L (IQR, 0.6-1.6 mg/L) and 25 patients
(55.6%) had an adequate posaconazole trough concentration of ≥ 1.2 mg/L. Over-
all, 30 patients (42.9%) received interacting comedication with a PPI/H2-receptor
antagonist, 7 patients (10.0%) received metoclopramide, 1 patient (1.4%) received
rifampicin, and 1 patient (1.4%) received fosamprenavir. The median duration of
treatment with posaconazole was 60 days (IQR, 26-103 days).
4.3.1 Posaconazole exposure
Univariate analysis showed a significant correlation of the posaconazole con-
centration with the albumin concentration (correlation coefficient 0.309; P = 0.014).
The median posaconazole concentration was significantly lower in patients suffer-
ing from vomiting or diarrhea, patients who received concomitant chemotherapy,
and in patients who received a PPI/H2-receptor antagonist (Table 4.2). Further-
more, the posaconazole concentration was significantly different in patients with a
different food intake. The median posaconazole concentration was 0.3 mg/L (IQR,
0.2-0.3 mg/L) in patients with a lack of enteral nutrition (and receiving TPN), 0.8
mg/L (IQR, 0.4-1.3 mg/L) in patients who had a nasogastric tube or a liquid diet,
and 1.3 mg/L (IQR, 0.8-2.1 mg/L) in patients with a normal diet (P < 0.001). The
median posaconazole concentration was similar in patients with different posaco-
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nazole dosing schedules, 1.0 mg/L (IQR, 0.6-1.7 mg/L) for 200 mg 3 times daily,
1.3 mg/L (IQR, 0.6-1.8 mg/L) for 200 mg 4 times daily, and 1.0 mg/L (IQR, 0.4-1.5
mg/L) for 400 mg 2 times daily (P = 0.780), in the univariate analysis. In the mul-
tiple linear regression analysis, variables obtained by the univariate analysis (albu-
min concentration, vomiting, diarrhea, chemotherapy, the use of a PPI/H2-receptor
antagonist, and food intake) and the posaconazole dose were included. The as-
sumptions for linear regression were met, the residuals of the log-transformed po-
saconazole trough concentration did not deviate from normality and the variance of
the residuals was considered homogeneous. The multiple linear regression analy-
sis showed a significant, independent, and negative association of the posaconazole
trough concentration with a lack of enteral nutrition (and receiving TPN), vomiting,
the use of a PPI/H2-receptor antagonist, a liquid diet, concomitant chemotherapy,
and a posaconazole dose of 400 mg 2 times daily (Table 4.3).
Table 4.2: Posaconazole concentration between patient groups. Posaconazole trough con-
centration expressed as median with interquartile range. Abbreviations: PPI, proton pump
inhibitor.
Characteristic Posaconazole concentration (mg/L) P valuea
Yes No
Gender (male) 1.0 (0.6-1.4) 1.2 (0.5-2.1) 0.461
Vomitting 0.3 (0.1-0.7) 1.2 (0.6-1.7) 0.006
Diarrhea 0.6 (0.4-1.1) 1.3 (0.6-2.1) 0.008
Chemotherapy 0.9 (0.4-1.4) 1.2 (0.6-2.1) 0.088
PPI / H2-antagonist 0.6 (0.3-1.1) 1.4 (0.8-2.2) < 0.001
Metoclopramide 0.9 (0.3-1.4) 1.1 (0.6-1.7) 0.444
a Determined by using the Mann-Whitney U test.
4.3.2 Treatment outcome and treatment optimization strategies
Of the 25 patients who received posaconazole for prophylaxis, 1 patient (4.0%)
had a breakthrough infection with a Rhizomucor species resistant to posaconazole.
Of the 45 patients who received posaconazole for the treatment of an IFD (age:
range 17-75 years), the outcome was classified as a complete response in 24 patients
(53.3%) and as a partial response in 8 patients (17.8%). A stable response was seen
in 6 patients (13.3%), progression of the disease was seen in 4 patients (8.9%), and 3
patients (6.7%) died during treatment with posaconazole. The median posaconazole
concentration was 1.4 mg/L (IQR, 0.8-2.1 mg/L) in patients with a successful treat-
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Table 4.3: Multiple linear regression model of factors significantly associated with the posa-
conazole concentration. Abbreviations: CI, confidence interval; PPI, proton pump inhibitor.
R2 of the model = 0.562, R2 change = –0.014, compared with the model with all variables
included.
Factor Effect 95% CI P value
Lack of enteral nutrition –1.140 –1.741 to –0.539 < 0.001
Vomiting –0.866 –1.671 to –0.061 0.035
PPI / H2-antagonist –0.627 –0.923 to –0.331 < 0.001
Nasogastric tube / liquid diet –0.512 –0.829 to –0.195 0.002
Concomitant chemotherapy –0.453 –0.758 to –0.147 0.004
Posaconazol frequency 2 times daily –0.405 –0.727 to –0.083 0.015
ment (complete or partial response), 1.0 mg/L (IQR, 0.5-1.2 mg/L) in patients with
a stable response, and 0.3 mg/L (IQR, 0.2-1.3 mg/L) in patients with treatment fail-
ure (fungal disease progression or death) (P = 0.010). The ordinal regression analysis
showed a significant association of the posaconazole trough concentration with the
treatment outcome, when corrected for the age of the patient and the time to recov-
ery of leukocytes. A higher posaconazole concentration (P = 0.001) and a lower age
of the patient (P = 0.005) were associated with a better treatment outcome, whereas
recovery of leukocytes was not associated with the outcome (Table 4.4).
Table 4.4: Ordinal regression model of the relationship of the posaconazole exposure with
treatment outcome. Abbreviations: CI, confidence interval; OR, odds ratio.
Factor OR 95% CI P value
Posaconazole concentration (mg/L) 22.22 3.40 to 145.33 0.001
Age (years) 0.92 0.86 to 0.97 0.005
Recovery of leukocytes (days) 1.00 0.96 to 1.05 0.841
In 5 patients (20%) in the prophylaxis group and in 8 patients (17.8%) in the treat-
ment group an attempt to increase the posaconazole concentration was performed.
In 4 out of 5 patients in the prophylaxis group and in 4 out of 8 patients in the
treatment group a therapeutic posaconazole concentration was achieved. Success-
ful strategies were a dose increase (4x 200 mg in the prophylaxis group, 4x 300 mg
and 4x 400 mg in the treatment group), discontinuation of the PPI, and the start of
enteral nutrition/increasing the food intake. In the other 5 patients, the posacona-
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zole concentration remained subtherapeutic after administering posaconazole with
an acidic beverage in 3 patients and the discontinuation of a PPI in 2 patients (of
which 1 patient had no enteral food intake).
4.4 Discussion
This study showed a subtherapeutic posaconazole concentration in 40% of the
patients receiving posaconazole prophylaxis and in 44% of the patients receiving
posaconazole treatment. Patients with a higher posaconazole concentration had a
better treatment outcome.
Multiple linear regression analysis showed that the posaconazole concentration
was significantly associated with the food intake of the patients. Both the lack of
enteral nutrition and a liquid diet had a negative effect on the posaconazole con-
centration, where the effect of no enteral nutrition was most powerful, which was in
accordance with earlier findings [11,21,30]. The absorption of posaconazole is signif-
icantly increased when posaconazole is administered with a (high-fat) meal [6, 30].
When patients are not able to eat or only eat small amounts of a liquid diet, it is
not likely that adequate posaconazole concentrations will be reached [30]. Further-
more, co-administration of posaconazole with a PPI or H2-antagonist had a negative
effect on the posaconazole concentration, due to a reduced absorption secondary
to a decrease in gastric acid production, and was in agreement with earlier stud-
ies [11, 12, 14, 15, 31, 32]. Administration of the posaconazole oral suspension to pa-
tients who are unable to eat or use a PPI/H2-antagonist should therefore be avoided.
The gastro-resistant tablet formulation of posaconazole that recently entered the
market [33] or the intravenous formulation [34] that has recently been approved
are more suitable for these patients. The posaconazole exposure of the tablet for-
mulation was not reduced when posaconazole was administered with medication
affecting gastric pH in healthy volunteers [33]. However, as for the oral suspen-
sion, the absorption of posaconazole from the tablet formulation is affected by food,
the posaconazole AUC increased by 51% when the tablet was administered with a
high-fat meal (compared to a 3- to 4-fold increase with the oral suspension) [35]. For
patients suffering from vomiting or who are unable to eat or tolerate oral medica-
tion, the intravenous formulation is the most obvious choice. The presence of diar-
rhea did not show a relation with the posaconazole exposure in the multiple linear
regression analysis. Since the oral suspension of posaconazole is predominantly dis-
solved in the stomach at low pH [30,33], the presence of problems with the intestine
is probably less important for the posaconazole absorption. Furthermore, the use of
chemotherapy during treatment with posaconazole was negatively associated with
the posaconazole exposure. The observed lower posaconazole concentration may be
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the result of a reduced absorption due to mucositis, or possibly mucosal dysfunc-
tion, villus atrophy, or damaged microbiota [11, 12]. Since posaconazole has a high
protein binding of> 98% [36], and half of the patients with chemotherapy had a low
albumin concentration, hypoalbuminemia can lead to an increased volume of dis-
tribution and an enhanced clearance of the free drug [8]. Hyper-hydration during
chemotherapy is not likely to explain the lower serum concentrations as posacona-
zole has a large volume of distribution of 7 to 25 L/kg [36]. Finally, the posaconazole
concentration was associated with the frequency of posaconazole administration in
the multiple linear regression analysis. A dose of 200 mg 4 times a day is recom-
mended in the Summary of Product Characteristics of posaconazole and a dose of
400 mg 2 times a day is suggested as an alternative [6]. Since a dose of 2 times 400
mg gives a lower posaconazole concentration, a more fractionated dose of 4 times
200 mg is a better approach to achieve a sufficient posaconazole exposure. A dose
of 2 times daily is possibly an option for patients who receive prolonged courses
of posaconazole treatment at home and have a normal food intake and do not use
medication that affects gastric pH. A study of Courtney et al. demonstrated that the
absorption of posaconazole was saturated at a dose of 800 mg [37]. However, this
study tested 800 mg as a single dose. Increasing the posaconazole dose to 1200-1600
mg a day in 4 divided doses led to an increased posaconazole trough concentration
in 2 patients. This strategy needs to be further studied in patients that receive the
oral suspension and have low posaconazole concentrations.
The patients with a successful treatment outcome had a significantly higher po-
saconazole concentration and there was a positive association of the posaconazole
concentration with the treatment outcome. The age of the patient was negatively as-
sociated with the treatment outcome. Older patients are likely to be more fragile and
have more comorbid medical conditions, which can possibly influence the treatment
outcome [38, 39]. We could not demonstrate an effect of the immune status (for the
duration of recovery of leukocytes as well as for the actual leukocyte count) of the
patients on the treatment outcome. Only a single leukocyte count, obtained at the
day of the posaconazole sample, was included in the analysis. The immune status
of the patient plays a role in the clearance of the infection; however, the influence of
the immune status could not be demonstrated with a single leukocyte count for each
patient. When including the duration of the recovery of leukocytes in the analysis,
we also could not demonstrate the influence of the immune status on the treatment
outcome. Since posaconazole was mainly used as salvage treatment, the leukocytes
of most patients already recovered, except for 8 out of 70 patients. Overall response
was favorable in 32 patients (71.1%), with a median posaconazole concentration of
1.4 mg/L in this patient group. Our results confirm that the posaconazole target con-
centration of at least 1.25 mg/L for salvage treatment of IA, which was proposed in
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the study of Walsh et al., is associated with a better outcome [16]. Due to the small
amount of patients receiving prophylaxis in our study, we cannot make a statement
about the proposed target concentration of 0.7 mg/L for prophylaxis.
A limitation of this study is its retrospective nature, although we expect selection
bias to be limited since posaconazole concentrations were measured routinely in our
hospital. In addition, we used strict criteria for completeness of the data for analysis
and we used the EORTC criteria for the evaluation of the treatment outcome. Due
to the retrospective nature of this study, we could not score the grade of the mu-
cositis, since this was not routinely scored. We therefore used the presence of diar-
rhea and chemotherapy during treatment with posaconazole as surrogate markers.
Furthermore, we used the first steady state trough concentration of posaconazole
for the analysis. However, these concentrations were representative for the whole
treatment course since we visually observed that posaconazole concentrations were
stable over time.
Since a large proportion of the patients had a low posaconazole exposure and
the exposure was associated with the treatment outcome, we believe that TDM has
added value for the treatment with posaconazole. Posaconazole was used as salvage
treatment in our hospital, which explains the large number of proven cases of IA and
the high number of non-Aspergillus infections. In case posaconazole is used as sal-
vage therapy for IA, with only few other alternatives left, or when posaconazole is
used as treatment for specific and life threatening IFD, for example caused by the
class of Zygomycetes [40, 41], maximizing the posaconazole exposure is warranted
and important for survival. We showed that a favorable outcome can be achieved
in salvage therapy with posaconazole in patients with higher posaconazole concen-
trations. Besides, posaconazole has been associated with an improved safety profile
compared to voriconazole and concentration-dependent adverse events have not
been identified to date [42]. With the new tablet and intravenous formulation, po-
saconazole is also suitable for patients with no food intake, absorption problems,
and the use of concomitant medication that affects gastric pH. Since the tablet can-
not be crushed or chewed, the oral suspension will remain a treatment option for
patients who are unable to take tablets, such as patients with dysphagia, which is
present in 16 to 23% of the general population [43, 44] and in up to 51% of criti-
cally ill patients [45]. The posaconazole oral suspension can also be used in patients
with a nasogastric tube, however, the posaconazole absorption is reduced in these
patients and TDM is therefore recommended to ensure sufficient posaconazole ex-
posure. The different posaconazole formulations in combination with TDM can help
to ensure sufficient posaconazole exposure and assure the efficacy of the antifungal
treatment. A prospective randomized clinical trial should be carried out to deter-
mine if therapeutic interventions, to increase the posaconazole exposure, result in
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an improved treatment outcome.
4.5 Conclusion
The posaconazole exposure was not sufficient in over 40% of patients at risk of
or with IFD and was negatively correlated with the lack of enteral nutrition, vom-
iting, the use of a PPI/H2-receptor antagonist, a liquid diet, chemotherapy, and a
posaconazole dose frequency of 2 times daily. A higher posaconazole concentration
was positively associated with a better treatment outcome. Therapeutic drug moni-
toring of posaconazole can detect underexposure in patients at risk of and with IFD
and can be helpful in treatment optimization.
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Chapter 5
Dried blood spot analy-
sis suitable for therapeutic drug monitoring of
voriconazole, fluconazole, and posaconazole
Abstract
Invasive aspergillosis and candidemia are important causes of morbidity and mortality in
immunocompromised and critically ill patients. The triazoles voriconazole, fluconazole,
and posaconazole are widely used for the treatment and prophylaxis of these fungal infec-
tions. Due to the variability of the pharmacokinetics of the triazoles among and within
individual patients, therapeutic drug monitoring is important for optimizing the efficacy
and safety of antifungal treatment. A dried blood spot (DBS) analysis was developed and
was clinically validated for voriconazole, fluconazole, and posaconazole in 28 patients.
Furthermore, a questionnaire was administered to evaluate the patients‘ opinions of the
sampling method. The DBS analytical method showed linearity over the concentration
range measured for all triazoles. Results for accuracy and precision were within accepted
ranges; samples were stable at room temperature for at least 12 days; and different hema-
tocrit values and blood spot volumes had no significant influence. The ratio of the drug
concentration in DBS samples to that in plasma was 1.0 for voriconazole and flucona-
zole and 0.9 for posaconazole. Sixty percent of the patients preferred DBS analysis as
a sampling method; 15% preferred venous blood sampling; and 25% had no preferred
method. There was significantly less perception of pain with the DBS sampling method
(P = 0.021). In conclusion, DBS analysis is a reliable alternative to venous blood sam-
pling and can be used for therapeutic drug monitoring of voriconazole, fluconazole, and
posaconazole. Patients were satisfied with DBS sampling and had less pain than with
venous sampling. Most patients preferred DBS sampling to venous blood sampling.
5.1 Introduction
Iinvasive aspergillosis and candidemia are important causes of morbidity andmortality in immunocompromised and critically ill patients [1–3] and are asso-
ciated with prolonged hospital stays and increased costs [2–5]. Prompt initiation of
antifungal therapy at the appropriate dose is required to improve outcomes in pa-
tients with invasive aspergillosis and candidemia [6–8]. The triazoles fluconazole,
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voriconazole, and posaconazole are widely used for the treatment and prophylaxis
of these fungal infections and are recommended as primary treatment by the Infec-
tious Diseases Society of America (IDSA) [1, 9].
Due to the variability of the pharmacokinetics of the triazoles among and within
individual patients, therapeutic drug monitoring (TDM) has been recommended by
the IDSA to optimize the efficacy and safety of the antifungal treatment [1, 6, 9].
Changes in clinical condition (e.g., hepatic and renal function), problems with ab-
sorption of the drug (posaconazole), nonlinear pharmacokinetics (voriconazole),
and drug-drug interactions can all contribute to the variability of pharmacokinet-
ics [1,6,9–13]. For voriconazole, trough concentrations in the range of 1.5 to 5 µg/ml
are important for the prevention of treatment failure and toxicity [14–16]. For po-
saconazole, concentrations of at least 0.7 µg/ml for prophylaxis and 1.5 µg/ml for
treatment are advised [17–20]. For adequate exposure to fluconazole, an area under
the concentration-time curve (AUC) of 400 mg*h/L is required [21–24]. Itraconazole
concentrations must be at least 0.5 µg/ml for prophylaxis and 1 µg/ml for adequate
therapy [6, 25, 26].
To extend the possibilities of TDM for patients at home and for hospitals without
an advanced bioanalytical infrastructure, dried blood spot (DBS) sampling, using a
finger prick instead of a venous blood sample, would be helpful. DBS analysis for
TDM has been demonstrated previously for other drugs used in infectious diseases,
such as anti-HIV, antimalaria, and antituberculosis drugs [27–30]. DBS analysis has
several advantages, including a less-invasive sampling procedure, a smaller sam-
pling volume, simpler storage and transfer of samples at room temperature, and no
biohazard risk during the shipment of samples [31–33]. The purpose of this research
was to develop and clinically validate a DBS analysis for voriconazole, fluconazole,
and posaconazole, and to evaluate the patients‘ opinions on the sampling method.
5.2 Materials and methods
5.2.1 Patients and sampling
From June 2012 to January 2013, patients receiving antifungal therapy with one
of the triazoles were recruited from departments and outpatient clinics of the Uni-
versity Medical Center Groningen, Groningen, the Netherlands. Patients aged ≥
18 years could participate if they were treated with voriconazole, fluconazole, or
posaconazole, a steady-state concentration was achieved, and routine TDM was
scheduled. Approval by the local ethics committee was not required, according
to Dutch law, because plasma samples were collected for routine care and a nonin-
vasive DBS sampling procedure was developed as an alternative to venous blood
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sampling in routine patient care. During implementation of the DBS analysis, pa-
tients were asked for consent at least 1 day before blood sampling was scheduled.
Venous blood and DBS trough samples were obtained before administration of
the antifungal drug. DBS samples were obtained through a finger prick with a lancet
puncture (BD Microtainer contact-activated lancet; 2.0 by 1.5 mm). The first drop of
blood was wiped and discarded; after that, the blood was dropped directly onto a
Whatman FTA DMPK-C paper card (GE Healthcare, the Netherlands). Venous dried
blood spot (VDBS) samples were prepared by pipetting 50 µL of venous whole blood
onto the paper cards. The remaining whole blood was centrifuged at 3,000 rpm for
5 minutes to obtain plasma, which was stored at –20◦C until analysis. The DBS and
VDBS samples were left to dry at room temperature for 3 hours and were stored in
sealed plastic bags with desiccant sachets at –20◦C until analysis.
5.2.2 DBS method validation
For analysis of the DBS, VDBS, calibration, and quality control (QC) samples of
voriconazole and posaconazole, an 8-mm-diameter disc was punched out. For anal-
ysis of the fluconazole samples, a 3-mm-diameter disc was punched out. Extraction
from the discs was performed by vortexing for 1 minute and sonication for 10 min-
utes using 200 µL of extracting solvent for voriconazole and posaconazole and 500
µL of extracting solvent for fluconazole. Due to the strong signal of fluconazole with
mass spectrometry (MS) and the larger concentration range (0.5 to 100 µg/ml for
fluconazole; 0.1 to 10 µg/ml for voriconazole and posaconazole), a smaller punch
size and a larger volume of extracting solvent were used for the extraction of flu-
conazole. The extracting solvent consisted of methanol-water (90:10, vol/vol), with
cyanoimipramine 0.05 µg/ml as an internal standard. Afterwards, the samples were
again vortexed for 1 minute, after which the extract was transferred to a vial with an
insert and was centrifuged at 11,000 rpm for 5 minutes. Subsequently, sample vol-
umes of 5 µL were analyzed using a previously validated liquid chromotography-
tandem MS (LC-MS/MS) method [34]. Plasma samples were prepared and ana-
lyzed using the same LC-MS/MS method. The DBS analytical method was vali-
dated in accordance with Guidance for Industry, Bioanalytical Method Validation
by the U.S. Food and Drug Administration [35]. DBS calibration and QC samples
were prepared by pipetting 50 µL of spiked venous whole blood onto DBS paper.
The linearity of the standard curve was assessed with 1/x2 weighting over a concen-
tration range of 0.1 to 10 µg/ml for voriconazole and posaconazole and 0.5 to 100
µg/ml for fluconazole. Within-run and between-run accuracy and precision were
evaluated for the QC samples at the lower limit of quantification (LLOQ) and at
levels designated low, medium, and high, corresponding to concentrations of 0.1,
0.5, 4.0, and 8.0 µg/ml for voriconazole and posaconazole and 0.5, 5.0, 40, and 75
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µg/ml for fluconazole. Each validation level was analyzed in quintuplicate, on 3
consecutive days. The degree of recovery was determined by comparing the extracts
from spiked DBSs at low, medium, and high concentrations to extracts of blank
DBSs subsequently spiked at low, medium, and high concentrations. Matrix effects
were determined by comparing extracts from blank DBSs subsequently spiked at
low, medium, and high concentrations with an extraction solvent (methanol-water
[90:10, vol/vol]) spiked at low, medium, and high concentrations. Stability was as-
sessed by storing low- and high-concentration DBS samples at room temperature
(20◦C), 37◦C, 50◦C, and –80◦C for 12 days. Furthermore, the effects of the hemat-
ocrit value and the blood spot volume on accuracy and precision were assessed for
hematocrit values of 25, 30, 35, 40, and 45% and for blood spot volumes of 30, 50, 70,
and 90 µL for low- and high-concentration control samples. For the method valida-
tion, the hematocrit value was standardized at 35% and the blood spot volume at 50
µL.
5.2.3 Patient preference
A questionnaire was developed to evaluate the patients‘ opinions on the sam-
pling method. Patients filled in the questionnaire themselves after the DBS sam-
pling. The questionnaire was based on previously published questionnaires on
quality of life [36, 37] and consisted of general questions on age, gender, employ-
ment, frequency of TDM for the triazole used, experience with finger prick sam-
pling, and questions on the venous and DBS sampling methods. Questions on the
sampling methods included the ease of performance and duration of the DBS sam-
pling, perception of pain for both methods, satisfaction with each sampling method,
and the method preferred. Perception of pain was measured by scoring pain on the
11-point numerical rating scale, where 0 is absolutely no pain and 10 is unbearable
pain [38].
5.2.4 Statistical analysis
In the analytical method validation, bias was defined as the difference between
the analytical result and the nominal concentration, expressed as a percentage. The
DBS method was validated by comparing the concentrations of the drug in the DBS
and VDBS with the concentration in plasma using Passing-Bablok regression and
Bland-Altman analysis (with Analyse-it software, version 2.20). Fisher‘s exact test
was used to evaluate the difference (expressed as a percentage) between subthera-
peutic posaconazole concentrations in the DBS before and after the use of the con-
version factor. For the evaluation of patient preference, answers on questions scored
on a scale were expressed as means with standard deviations (SD). Answers on yes-
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or-no questions were expressed as the percentage of patients answering ”yes”. The
paired sample t test was used to compare means, and McNemar’s test for paired
data was used to evaluate the differences in satisfaction with the two sampling
methods. Statistical analyses were performed using SPSS for Windows, version 20.0.
A P value of < 0.05 was considered statistically significant.
5.3 Results
5.3.1 Patient demographics and dose characteristics
Twenty-eight patients with a mean age of 54 years participated in the clinical
evaluation of the DBS analysis. The baseline characteristics of the patients are shown
in Table 5.1. Most patients received antifungal therapy for candidiasis (n = 9 [32.1%])
or (suspected) invasive aspergillosis (n = 7 [25.0%]). Other fungal infections were
caused by Scedosporium prolificans, Hormograffiella aspergillata, or Absidia corymbifera.
Voriconazole was dosed at 150 to 400 mg twice daily and fluconazole at 150 to 200
mg once daily. Posaconazole dosages ranged from 300 to 400 mg twice daily to 200
mg 3 or 4 times a day.
5.3.2 DBS method validation
The DBS analytical method showed good linearity over the concentration range
for all triazoles. The regression equations were 0.000219 + 0.373 x response for
voriconazole, 0.00159 + 0.0141 x response for fluconazole, and 0.00245 + 0.0558 x
response for posaconazole. The correlation coefficients (r2) were 0.997 for voricona-
zole, 0.993 for fluconazole, and 0.991 for posaconazole. The mean measured concen-
tration was between 91.1 and 105.2% of the nominal concentration for all triazoles.
Within-run and between-run coefficients of variation (CV) were between 5.6 and
10.8% and 0.0 and 13.1%, respectively, and well within the required range of < 20%
for the LLOQ level and< 15% for the low-, medium-, and high-concentration levels.
The level of recovery by extraction from the DBS and the bias caused by variable ma-
trices were between 84.9 and 112.1% and between 89.4 and 109.5%, respectively, for
all triazoles, and within the required range of 15%. Furthermore, samples were sta-
ble at room temperature (20◦C), 37◦C, 50◦C, and –80◦C for 12 days (–10.0 to 14.2%).
The bias in hematocrit values of 25 to 45% ranged from –15.3 to 18.6%, compared
with samples with a standardized hematocrit of 35%. The bias in blood spot vol-
umes of 30 to 90 µL ranged from –13.2 to 14.8%, compared with samples with a
standardized blood spot volume of 50 µL.
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Table 5.1: Patient characteristics.
Characteristic No. of patients (%)
Gender (male) 19 (67.9%)
Mean age (years) (range) 54 (19 - 67)
Underlying condition
Hematological malignancy 25 (89.3%)
Lung transplantation 2 (7.1%)
Hemoptysis 1 (3.6%)
Fungal infection
Candida albicans 4 (14.3%)
Candida glabrata 2 (7.1%)
Candida krusei 2 (7.1%)
Candida tropicalis 1 (3.6%)
Aspergillus fumigatus 3 (10.7%)







Mean hematrocrit (%) (range) 34.7 (20.4 - 46.8)
5.3.3 Clinical validation
Thirty samples from 28 patients were included in the clinical validation of the
DBS analysis (Table 5.2). The results of the Passing-Bablok regression between DBS
and plasma samples are shown in Figure 5.1. The slope of the regression line was 1.0
for voriconazole and fluconazole and 0.9 for posaconazole. To compensate for the
difference between the concentrations of posaconazole in DBS and plasma samples,
a conversion factor of 1.1 was used to calculate the corresponding concentration in
plasma from the concentration in the DBS. With Bland-Altman analysis, the absolute
difference between the concentrations in DBS and plasma samples versus the mean
concentration in DBS ans plasma samples was 0.0 (95% confidence interval [95%
CI], –0.22 to 0.22) for voriconazole, –0.33 (95% CI, –0.55 to –0.11) for fluconazole,
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Figure 5.1: Clinical validation of DBS analysis by Passing-Bablok regression between drug
concentrations in DBSs and plasma. For fluconazole (n = 11), the regression line has a slope
of 0.98 (95% CI, 0.79 to 1.24) and an intercept of –0.23 (95% CI –1.43 to 0.52). For posaconazole
(n = 8), the regression line has a slope of 0.92 (95% CI, 0.67 to 1.14) and an intercept of –0.10
(95% CI, –0.33 to 0.15). For voriconazole (n = 11), the regression line has a slope of 1.0 (95%
CI, 0.86 to 1.17) and an intercept of 0.10 (95% CI, –0.12 to 0.20).
limits of agreement for voriconazole and posaconazole. For fluconazole, 10 out of 11
values were within the 95% limits of agreement, and all values were within the 99%
limits of agreement. Passing-Bablok regression and Bland-Altman analysis of drug
concentrations in VDBS versus plasma samples showed results similar to those for
concentrations in DBS samples for all triazoles; all values were within the 95% limits
of agreement (data not shown).
The voriconazole concentration was subtherapeutic in 4 patients (40%), rang-
ing from 0.1 to 1.0 µg/ml, and was considered toxic (9.9 µg/ml) in 1 patient (10%).
Among patients receiving posaconazole for prophylaxis, 3 (75%) had a trough con-
centration in the therapeutic range (> 0.7 µg/ml) and 1 (25%) had a trough con-
centration of 0.2 µg/ml. Among patients receiving posaconazole for treatment, the
trough concentration was in the therapeutic range (> 1.5 µg/ml) in 2 patients (50%)
and ranged from 1.0 to 1.3 µg/ml in the other 2 patients (50%). Before the use of
the conversion factor, the DBS posaconazole concentration was subtherapeutic in 4
patients (50%). After the conversion factor of 1.1 was introduced, the DBS posaco-
nazole concentration was subtherapeutic in 3 patients (37.5%) (P = 0.071).
5.3.4 Patient preference
Ten hospitalized patients and 10 patients from the outpatient clinic with a mean
age of 55 years (range, 30 to 67 years) completed the questionnaire after the DBS
sampling. Fifteen patients (75%) were male; 10 patients (50%) had paid employ-
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ment; 6 patients (30%) were unemployed due to their illness; and 4 patients (20%)
were unemployed due to other reasons, such as retirement. Most patients (60%)
had no experience with blood sampling by a finger prick; six patients (30%) had
experience with sampling by a finger prick due to diabetes; and 2 patients (10%)
had experienced sampling by a finger prick by a nurse in the past. The average
frequency of TDM for one of the triazoles was 1.9 (SD, 1.6) times a month. Re-
sults of the comparison of DBS sampling with venous blood sampling are shown
in Table 5.3. Twelve patients (60%) preferred DBS analysis as a sampling method; 3
patients (15%) preferred venous blood sampling; and 5 patients (25%) had no pre-
ferred method. The perception of pain was significantly less for the DBS sampling
method (patients gave DBS sampling a score of 1.4 on the 11-point numerical rating
scale, compared to 2.1 for venous sampling [P = 0.021]).
5.4 Discussion
A DBS analysis for voriconazole, fluconazole, and posaconazole was developed,
clinically validated, and implemented in daily practice. The concentrations of all tri-
azoles in DBS samples were in good agreement with those in plasma. Previous stud-
ies on DBS analysis showed that the hematocrit value and the blood spot volume
may influence the analysis results for DBS samples [31–33, 39]. For analysis of the
triazoles, the hematocrit value and blood spot volume had only a minor influence.
The mean hematocrit value in patients was 34.7%, which was in good agreement
with the standardized hematocrit value of 35%. Concentrations of posaconazole in
plasma were slightly higher than those in DBSs. This difference might be caused
by a difference in protein binding, which is > 98% for posaconazole [18], or the
different distribution of the drug in whole blood and plasma, since the same differ-
ence was also observed between concentrations in VDBS ans plasma samples [39].
Although labeled isotopes are preferred as internal standard when mass spectrom-
etry is used, with the use of cyanoimipramine as an internal standard, no ion sup-
pression was observed during analysis of six lots of pooled human serum and the
simultaneously direct infusion of a stock solution containing fluconazole, voricona-
zole, or posaconazole and cyanoimipramine [34]. Itraconazole was not included in
the method analysis, because itraconazole is rarely used due to hospital policy in
favor of voriconazole and posaconazole for invasive aspergillosis and fluconazole
for candidemia, in accordance with the IDSA guidelines [1, 9]. However, a DBS
analysis of itraconazole can be useful if the drug is used for treatment or prophy-
laxis [1, 6, 25, 26].
A method to simultaneously quantify triazoles in plasma spotted onto dry sam-
ple spot devices was developed previously [40]. However, fluconazole was not in-
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cluded in this method, and validation was performed only with plasma spotted
onto paper cards and not with patients‘ DBS samples. Differences in protein bind-
ing and in the distribution of a drug between whole blood and plasma can lead to
different concentrations of the drug in whole blood versus plasma. Furthermore, the
concentration of a drug in capillary blood obtained by finger pricking is a mixture
of venous and arterial blood and mimics arterial rather than venous sampling [39].
Clinical validation with patients‘ DBS samples is therefore required to make sure
DBS samples can be used as a substitute for plasma samples. Finally, no evaluation
of the patients‘ opinions was included.
Our evaluation of the patients‘ opinions of the sampling method showed that
most patients preferred DBS sampling to venous blood sampling. Major advantages
of DBS sampling were that patients experienced significantly less pain and did not
have to travel to the hospital for blood sampling. A limitation was that the question-
naire was not validated, although it was based on validated questionnaires. Since
patients filled in the questionnaire themselves, and since it consisted of objective
questions and scoring systems, we do not expect a large bias.
With DBS analysis, patients can obtain the DBS samples themselves. Previous
studies with DBS analysis of antiretroviral and immunosuppressive drugs showed
that 87.5 to 98% of the DBS samples obtained by patients were suitable for analy-
sis [41, 42]. Besides, when the samples are sent by mail, the physician already has
the results of the analysis before the consultation. Furthermore, with DBS sampling,
samples do not have to be obtained solely during office hours. DBS samples can
be shipped to assigned hospitals for the determination of triazole concentrations,
because these samples are stable at room temperature, and shipping them presents
no biohazard risk [31–33]. TDM of the triazoles can be performed frequently, and
patients can receive prolonged courses of antifungal treatment for invasive or re-
fractory fungal infections. Through self-sampling and mailing of DBS samples, the
costs for personnel performing venous blood sampling, traveling costs for patients,
and costs to patients due to loss of working days can be saved [31].
Although detection of subtherapeutic or toxic trough concentrations of drugs
(which is important for the success rate of antifungal therapy) was not the aim of
this research, the DBS analysis revealed such concentrations in 50.0% of the patients
receiving voriconazole and in 37.5% of the patients receiving posaconazole. The
results of the DBS analysis show the necessity and relevance of TDM for optimiz-




In conclusion, a DBS analysis was successfully developed and clinically vali-
dated for voriconazole, fluconazole, and posaconazole. Patients were satisfied with
DBS sampling, and most patients preferred DBS sampling to venous blood sam-
pling. Besides, patients had significantly less pain with DBS sampling. With this
DBS analysis, the possibilities of TDM of the triazoles can be extended to patients at
home and to hospitals without an advanced bioanalytical infrastructure.
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Table 5.2: Concentrations of drugs in patient plasma, DBS, and VDBS samples.
Concn (mg/L) of drug in:
Drug and sample Plasma DBS VDBS
Voriconazole
Sample 1 0.1 0.1 0.1
Sample 2 0.4 0.5 0.5
Sample 3 0.7 0.8 0.8
Sample 4 1.0 1.3 1.2
Sample 5 1.6 1.4 1.9
Sample 6 1.6 1.5 2.0
Sample 7 1.9 2.1 2.1
Sample 8 2.5 2.9 3.0
Sample 9 3.7 3.1 -
Sample 10 4.2 4.5 4.6
Sample 11 9.9 9.4 10.7
Fluconazole
Sample 1 2.8 2.5 2.8
Sample 2 3.0 2.5 2.9
Sample 3 3.0 3.1 2.9
Sample 4 3.4 3.2 3.9
Sample 5 3.9 3.2 3.6
Sample 6 4.6 4.1 4.3
Sample 7 4.7 4.4 5.2
Sample 8 4.8 4.2 4.5
Sample 9 5.7 6.1 5.8
Sample 10 6.3 5.7 5.9
Sample 11 6.9 6.5 6.0
Posaconazole
Sample 1 0.2 0.1 0.1
Sample 2 0.8 0.6 0.6
Sample 3 0.8 0.7 0.8
Sample 4 1.0 0.8 0.9
Sample 5 1.1 0.8 0.9
Sample 6 1.3 1.3 1.3
Sample 7 2.1 1.8 1.8
Sample 8 1.8 1.6 -
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Table 5.3: Patients‘ opinions on the DBS and venous blood sampling methodsa.
Valueb for:
Venous DBS
Question sampling sampling Pc
Discomfort of traveling to hospital 2.4 (1.5) NA
Hindrance to social activities 1.3 (0.7) 1.1 (0.3) 0.331
Hindrance to work activities 1.5 (0.9) 1.2 (0.7) 0.309
Perception of pain 2.1 (2.0) 1.4 (1.3) 0.021
Satisfaction with sampling method 80 90 0.375
(% answering yes)
Sampling time (min) NA 4.4 (3.4)
Hindrance to self-sampling DBS NA 2.3 (1.7)
DBS sampling easy to carry out NA 100
(% answering yes)
Advantage not traveling to hospital NA 80
(% answering yes)
a Twenty patients filled out the questionnaire.
b Values are mean scores (SD) except where otherwise indicated. On the scale of discomfort or hin-
drance, from 1 to 5, 1 is no hindrance and 5 is serious hindrance. On the 11-point numerical rating
scale for the perception of pain, 0 is absolutely no pain and 10 is unbearable pain. NA, not applicable.
c The paired sample t test was used to compare means, and the McNemar test for paired data was used
to evaluate the difference in satisfaction with the two sampling methods.
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Chapter 6
Simultaneous quantification of
anidulafungin and caspofungin in plasma by
an accurate and simple liquid chromatography
tandem mass spectrometric method
Abstract
Introduction. Echinocandins are a valuable addition for the treatment of invasive fun-
gal infections, as they are efficacious, demonstrate low toxicity, and have limited drug-
drug interactions. In specific clinical situations when altered pharmacokinetics can be
expected or dosing guidelines are conflicting, it may be useful to measure concentra-
tions. For this purpose, a liquid chromatography-tandem mass spectrometric method to
measure anidulafungin and caspofungin in ethylenediaminetetraacetic acid plasma was
developed.
Methods. The method was developed on a Thermo Fisher TSQ Quantum LC-MS/MS.
For separation, a BetaBasic C4 (100 mm x 3.0 mm; 5 µm) analytical column was used.
Sample preparation consisted of protein precipitation directly in the autosampler vial.
The internal standard aculeacin A is structurally related, not used in humans, and com-
mercially available. The method was validated according to the guidelines for bioanalyt-
ical method validation of the Food and Drug Administration.
Results. The method was accurate (bias ranging from –3.0% to 1.9%) and precise
(within-run and between-run coefficients of variation of 2.2% to 7.7% and 1.6% to
9.0%, respectively). All calibration curves were linear over a range of 0.5 - 10.0 mg/L
for anidulafungin and 0.1 - 20.0 mg/L for caspofungin, and if necessary, samples can be
diluted 10-fold. The samples were stable for 3 freeze-thaw cycles, with a bias ranging
from 0.6% to 11%. The maximum bias from the worst storage condition, 72 hours at
room temperature, was –14.7%. In patient samples, anidulafungin peak concentrations
ranged from 2.8 to 8.6 mg/L (n = 20) and trough concentrations ranged from 1.0 to 4.7
mg/L (n = 79). The measured caspofungin concentrations ranged from 1.9 to 7.3 mg/L
(n = 20).
Conclusions. The method developed has a straightforward sample preparation and uses
a structural analog as the internal standard. This method has been applied successfully
for the measurement of anidulafungin and caspofungin concentrations in patient sam-




chinocandins are a valuable addition for the treatment of invasive fungal infec-
tions, as they are efficacious, demonstrate low toxicity, and have limited drug-
drug interactions [1]. A good predictor of in vitro and in vivo efficacy of these an-
tifungal drugs seems to be the area under the concentration-time curve (AUC) di-
vided by the minimum inhibitory concentration (MIC) [2]. The AUC/MIC ratio
has an impact on the mortality of patients with invasive Candida infections, which
was earlier shown for fluconazole [3]. Although no clinical data are available to
show a similar relationship for echinocandins, it may be useful to measure concen-
trations in specific clinical situations in which altered pharmacokinetics can be ex-
pected and dosing guidelines are conflicting. A typical situation in daily practice is
dosing caspofungin in a patient weighing over 80 kg with hepatic impairment [4,5].
In this case, a clinician has to choose between an increased dose based on body
weight or a decreased dose based on the hepatic impairment. Another situation
in which dosage guidelines are conflicting is when caspofungin and rifampicin are
used concomitantly in a patient with hepatic impairment. The options are an in-
creased dose based on the drug-drug interaction [6] or a decreased dose based on
the hepatic impairment. In these cases, it would be informative and decision sup-
portive to be able to measure plasma concentrations of echinocandins. Although liq-
uid chromatography-tandem mass spectrometric (LC-MS/MS) methods have been
described for the determination of anidulafungin [7] or caspofungin [8] alone and
for the simultaneous quantification of echinocandins and azoles [9, 10], they have
several limitations. Time-consuming sample preparation and diluting steps [8–10],
use of online solid-phase extraction [7], or expensive ultraperformance liquid chro-
matography [10], are major drawbacks for routine analysis. But, most importantly,
some methods [7, 10] do not use an internal standard that structurally resembles
the echinocandins, such as a structural analog or stable label. This should be dis-
couraged because internal standards that are not structurally related are less able to
compensate for unavoidable variances [11].
To overcome the problems with current methods of analysis our objective was to
develop an accurate and simple LC-MS/MS method for the simultaneous quantifi-
cation of anidulafungin and caspofungin, with straightforward sample preparation.
6.2 Materials and methods
6.2.1 Chemicals and reagents
Anidulafungin was provided by Pfizer (New York), and caspofungin was sup-
plied by Merck Sharp & Dohme (Whitehouse Station, NJ). A structural analog for




Figure 6.1: Chemical structures of the internal standard aculeacin A (A), anidulafungin (B),
and caspofungin (C).
the echinocandins, aculeacin A (Fig. 6.1), was obtained from Sigma-Aldrich (St.
Louis, MO). Acetonitrile, trifluoroacetic anhydride, and water for LC-MS were pur-
chased from BioSolve (Valkenswaard, The Netherlands). Methanol Lichrosolv and
formic acid were from Merck KGaA (Darmstadt, Germany). Acetic acid (100%),
ammonium acetate, and ammonium formate (98%-100%) were from Acros Organ-
ics (Geel, Belgium). All reagents were of suitable analytical grade. Ultrapure water
was obtained from a Milli-Q water purifying system (Millipore Corporation, Biller-
ica, MA).
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The precipitation reagent consisted of 0.5 mg/L internal standard in a solution
containing 3 g/L formic acid and 180 mg/L ammonium formate in acetonitrile-
methanol (10:3 [vol/vol]). High-performance liquid chromatography eluent A was
an aqueous buffer (pH 3.5) containing ammonium acetate (5 g/L), acetic acid (35
mg/L), and trifluoroacetic anhydride (2 mL/L) in water. Water and acetonitrile
were used as high-performance liquid chromatography eluents B and C, respec-
tively.
6.2.2 Equipment
All experiments were performed on a triple-stage quadrupole LC-MS/MS (TSQ
Quantum; Thermo Fisher, San Jose, CA) with a Finnigan Surveyor MS pump and a
Finnigan Surveyor autosampler (Thermo Fisher). The TSQ Quantum mass-selective
detector was operated in selected reaction monitoring mode with positive electro-
spray ionization. Xcalibur software version 2.0 SR1 (Thermo Fisher) was used for
peak height integration for all components. For separation, a BetaBasic C4 (100 x 3.0
mm; 5 µm particle size; Thermo Fisher) analytical column was used.
6.2.3 Calibrators and quality control samples
Stock solutions were prepared in methanol-water (50:50 [vol/vol]). For the prepa-
ration of the calibration standards, 2 individual stock solutions were prepared, with
1000 mg/L anidulafungin or 1000 mg/L caspofungin. These stock solutions were
diluted to obtain working stock solutions with either 100 mg/L anidulafungin or
100 mg/L caspofungin.
Separate stock solutions, containing 1000 mg/L anidulafungin or 1000 mg/L
caspofungin, were made for the preparation of the quality control (QC) samples.
Working stock solutions with either 100 mg/L anidulafungin or 100 mg/L caspo-
fungin were obtained after dilution.
The calibration and QC samples were prepared by spiking pooled ethylenedi-
aminetetraacetic acid (EDTA) plasma with the prepared stock solutions and work-
ing stock solutions. For the concentrations used, see Table 6.1. The calibration sam-
ples and QC samples were stored at –20◦C.
6.2.4 Sample processing
In a 2-mL glass autosampler vial, 100 µL of EDTA plasma and 500 µL of precip-
itation reagent were vortexed for 1 minute on a Lab-tek multitube vortexer (Christ-
church, New Zealand). The vials were stored at –20◦C for 30 minutes to promote
protein precipitation. Afterwards, the vials were vortexed again for 1 minute. For
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Table 6.1: Concentrations of calibration standards.
Drug Calibrator concentration (mg/L) QC sample concentrations (mg/L)
LLOQ Low Medium High
Anidulafungin 0.5; 1; 1.25; 1.50; 2.5; 3.75; 5; 6.25; 7.5; 10 0.5 1.25 5.0 8.0
Caspofungin 0.1; 0.25; 0.5; 1; 2.5; 5; 7.5; 10; 15; 20 0.1 0.5 10.0 16.0
the last preparation step, the vials were centrifuged at room temperature for 5 min-
utes at 10,164 g (11,000 rpm) in a Hettich benchtop centrifuge (Mikro 22 centrifuge;
Hettich, Ba¨ch, Switzerland). From the clear upper layer of the samples, 5 µL was
injected into the LC-MS/MS.
6.2.5 LC-MS/MS conditions
The eluent gradient was tuned in such a way that all compounds were baseline
separated (Table 6.2). The flow rate was 250 µL/min and the column was kept at
room temperature. The temperature in the autosampler was set at a temperature of
10◦C. The ion source spray voltage was set at 3500 V and the capillary temperature
at 350◦C. Nitrogen was used as sheath and auxiliary gas, pressures were set at 35
and 5 (arbitrary units), respectively. Argon was used as collision gas. The scan time
was 0.050 seconds at a scan width of 0.5 m/z. The following m/z transitions of
precursor ions to product ions were used: anidulafungin 1140.7 → 343.2 (collision
energy, 61 eV), caspofungin 547.4→ 538.0 (collision energy, 11 eV), and aculeacin A
1036.7→ 1018.7 (collision energy, 15 eV).
6.2.6 Calibration and calculation
The calibration curves were constructed using a linear regression of the ratios of
the observed peak heights of either anidulafungin or caspofungin and the internal
standard aculeacin A against the spiked concentrations of the standards. The con-
centration of patient samples was determined based on a 1-point calibration. The
highest calibrator concentration was used for the 1-point calibration. The results
from the 1-point calibration were only valid if the bias of the control sample (plasma
spiked with anidulafungin [1.0 mg/L] and caspofungin [2.0 mg/L]) was less than
15%.
6.2.7 Method validation
In accordance with the Guidance for Industry Bioanalytical Method Validation
of the Food and Drug Administration [12], method validation included selectivity,
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Table 6.2: Gradient elution program.
Time (min) Solvent A (%) Solvent B (%) Solvent C (%)
0.0 5.0 75.0 20.0
1.0 5.0 35.0 60.0
2.0 5.0 35.0 60.0
3.2 5.0 20.0 75.0
3.5 5.0 5.0 90.0
4.0 5.0 0.0 95.0
9.0 5.0 0.0 95.0
10.0 5.0 75.0 20.0
Solvent A, aqueous buffer with pH 3.5 (ammonium acetate 5 g/L, acetic acid 35 mg/L, and trifluo-
roacetic anhydride 2 mL/L in water); solvent B, ultrapure water; solvent C, acetonitrile.
linearity, accuracy, precision, sensitivity, recovery, and stability. Precision was sub-
divided into within-run and between-run precision. On each of the 4 analytical
days, a single calibration curve was obtained and the QC samples were analyzed in
5 replicates.
Selectivity and sensitivity
The selectivity of this method was evaluated by analyzing 6 lots of pooled EDTA
plasma. Sensitivity was examined by comparing the response of 6 lots of pooled
blank EDTA plasma with the response of lower limit of quantification (LLOQ) sam-
ples. The possible existence of ion suppression or ion enhancement was determined
by analyzing 6 lots of pooled EDTA plasma during simultaneous post-column con-
tinuous infusion of a stock solution containing 15 mg/L anidulafungin, caspofun-
gin, and internal standard by a syringe pump at a flow rate of 10 µL/min [13].
Accuracy and precision
The accuracy and precision of the method were determined by analyzing QC
samples of 4 concentrations in 5-fold on 4 different days. The responses were ana-
lyzed using 1-way ANOVA for each single concentration level. The bias of the mean
from the true value served as the measure of accuracy. The precision was calculated
as the coefficient of variation of the concentrations within a single run (within run)
and of the concentrations in the runs on the different days (between run).
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Recovery
The recovery was determined at 3 concentrations (low, medium, and high) using
5 replicates of each by comparison of the mean peak height in plasma with the mean
peak height of samples prepared in a nonbiological matrix (precipitation reagent
without internal standard).
Stability
Stability tests included 3 freeze-thaw cycles, storage stability, and autosampler
stability. For the freeze-thaw stability test, samples with low and high concentra-
tions were stored at –20◦C. After 3 cycles of freeze-thaw, the concentration was com-
pared with the mean concentration of the freshly prepared samples. In addition, the
stability of anidulafungin and caspofungin in plasma was determined after 24, 48,
and 72 hours of storage in the refrigerator at +4◦C and at room temperature. The
stability of processed samples in the autosampler was also evaluated after residing
24, 48, and 72 hours in the autosampler.
Dilution integrity
On 4 consecutive days, a sample with a concentration of 25 mg/L for anidulafun-
gin or caspofungin was diluted 10-fold, processed in 5 replicates and then analyzed.
Matrix comparison
The calibration curves of anidulafungin and caspofungin resulting from calibra-
tors prepared in sodium heparin plasma and serum were compared and analyzed
by 1-way ANOVA with the calibration curve from the samples prepared in EDTA
plasma.
6.2.8 Application of the method
This method has been used in our hospital, both for research and for clinical
practice. For a clinical trial (NCT01047267) on the pharmacokinetics of anidula-
fungin in critically ill patients, samples from 20 patients were measured. The study
protocol was approved by the local institutional ethics committee. Written informed
consent was obtained from the patient or the legal representative of the patient. In
addition, anidulafungin and caspofungin concentrations were measured in selected
patients. For caspofungin, special attention was paid to pediatric patients and pa-
tients weighing more than 80 kg with elevated liver enzymes. Besides this, concen-
trations were measured in neutropenic patients treated with anidulafungin.
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6.3 Results
The retention times of anidulafungin, caspofungin, and aculeacin A were 5.0,
4.3, and 5.6 minutes, respectively. Figure 6.2 shows ion chromatograms of a sample
spiked at LLOQ and a blank sample.
Selectivity and sensitivity
There were no peaks observed in any of the pooled blank EDTA plasma samples
at the retention time of the echinocandins or the internal standard. No ion suppres-
sion or ion enhancement was observed.
Linearity, accuracy, and precision
All calibration curves were linear over a range of 0.5 - 10.0 mg/L for anidula-
fungin and 0.1 - 20.0 mg/L for caspofungin. The mean equations were y = 0.158x
+ 0.00343 (R2 = 0.996) for anidulafungin and y = 0.877x + 0.00780 (R2 = 0.999) for
caspofungin. For patient samples, a 1-point calibration was used because of the
linearity of the calibration curves and the practically zero intercept. The results of
accuracy and precision tests are listed in Table 6.3.
Recovery
The recovery of anidulafungin and caspofungin ranged from 104.4% to 106.7%
and from 91.4% to 114.7%, respectively. The internal standard, aculeacin A, had a
recovery of 96.9%. All coefficients of variation were less than 7%.
Stability
The samples were stable for 3 freeze-thaw cycles, with a bias ranging from 0.6%
to 11%. The maximum bias from the worst storage condition, room temperature,
was –14.7%.
Dilution integrity
The mean concentration of the diluted plasma samples was 2.57 mg/L (undi-
luted: 25.0 mg/L) for anidulafungin with a bias of 3% and 2.49 mg/L (undiluted:
25.0 mg/L) for caspofungin with a bias of –1%.
Matrix comparison
There was no significant difference between the slope and the intercept of the
calibration curves of anidulafungin and caspofungin in sodium heparin plasma or
serum in comparison with those of the calibration curve in EDTA plasma.
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Figure 6.2: Ion chromatograms for aculeacin A (A), a LLOQ sample of anidulafungin (B)
and caspofungin (C), and ion chromatograms of a blank EDTA plasma sample at the ion


























































































6.3.1 Application of the method
This method of analysis for anidulafungin and caspofungin has been used for
more than 1 year in our hospital. For a clinical trial (NCT01047267) on the pharma-
cokinetics of anidulafungin in critically ill patients, samples from 20 patients were
measured. The peak concentrations (n = 20) ranged from 2.8 to 8.6 mg/L. For each
patient, more than 1 trough concentration was measured. The anidulafungin trough
concentrations (n = 79) ranged from 1.0 to 4.7 mg/L. In addition, anidulafungin con-
centrations were measured in neutropenic patients. Figure 6.3A shows an ion chro-
matogram following protein precipitation of an anidulafungin trough concentration
sample from a neutropenic patient.
Caspofungin concentrations were measured in 8 patients with elevated liver en-
zymes. In 2 infants, a peak (end of infusion) and trough concentrations were mea-
sured. A 5-year-old boy, with a traumatic pancreas rupture, received 42 mg (50
mg/m2) caspofungin after a loading dose of 60 mg (70 mg/m2). Caspofungin peak
and trough concentrations were 10.8 and 1.9 mg/L, respectively. Another 8-year-old
boy, with liver failure after liver transplantation, received 50 mg caspofungin after
a loading dose of 70 mg. Caspofungin peak and trough concentrations were 11.4
and 3.3 mg/L, respectively. The measured caspofungin concentrations (n = 20) in
adult patients ranged from 1.9 to 7.3 mg/L. Figure 6.3B shows an ion chromatogram
following protein precipitation of a caspofungin trough concentration sample from
an overweight patient (103 kg) with elevated liver enzymes.
6.4 Discussion
We developed an accurate and simple LC-MS/MS method, which proved to be
suitable for routine monitoring of anidulafungin and caspofungin. The method
was validated according to the guidelines for bioanalytical method validation of
the Food and Drug Administration [12].
One of the advantages of our method, compared with the methods currently
available, is the internal standard, aculeacin A. When stable isotope-labeled inter-
nal standards are not available, a structural analog is preferred as the internal stan-
dard [11]. Aculeacin A, isolated from Aspergillus aculeatus [14], is structurally related
to the echinocandins, not used in humans, and commercially available. Previously
reported methods use ascomycin, an ethyl analog of tacrolimus [7], or deuterated
voriconazole [10] as internal standard. These internal standards have the disadvan-
tage that they are not structurally related to the echinocandins and are, therefore,
less able to compensate for the unavoidable variances in the method. The 2 meth-
ods that do use a structurally related internal standard [8, 9] chose a derivate of
caspofungin as internal standard, which is not commercially available.
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Figure 6.3: Ion chromatogram following protein precipitation of a trough concentration (2.6
mg/L) from a patient receiving a maintenance dose of 100 mg anidulafungin once daily (A)
and of a trough concentration (1.9 mg/L) from a patient receiving a maintenance dose of 70
mg caspofungin once daily (B).
The method we used for sample preparation is rather straightforward. Although
all previously published methods used protein precipitation in sample preparation,
most used a more complex sample preparation. Farowski et al. used diluted plasma
as matrix, which is obtained after centrifuging diluted blood layered onto a double-
discontinuous Ficoll-Hypaque density gradient and another dilution step [9]. The
sample preparation method described by Decosterd et al. [10] and Rochat et al. [8]
required an additional dilution step, which may result in an increased risk of errors
and an elevated assays variance.
The choice of the matrix does not seem to affect the analysis. No differences
were observed in matrix comparisons between serum and plasma (heparin and
EDTA). This observation is consistent with previously published results. However,
the stability of samples seems to be influenced by the matrix. At room tempera-
ture, anidulafungin and caspofungin are more stable in EDTA plasma than in citrate
plasma [10] or serum (results not shown).
The simple sample workup procedure contributed to the slightly increased LLOQ
of our method for analysis of anidulafungin compared with the LLOQ of previ-
ously described methods [7, 9, 10]. No clinical implications are expected because
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the anidulafungin trough concentrations measured in this study, and previously re-
ported anidulafungin trough concentrations [15–17], were above our LLOQ.
6.5 Conclusion
In conclusion, a simple and accurate method for determination of anidulafun-
gin and caspofungin in plasma has been developed. This method has already been
successfully applied to the measurement of anidulafungin and caspofungin concen-
trations in patient samples.
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Chapter 7
Plasma concentrations of
caspofungin at two different dosage regimens
in a patient with hepatic dysfunction
Abstract
The currently recommended dosage regimen of caspofungin (50 mg/day) was developed
for patients with invasive candidiasis. With invasive aspergillosis, successful outcomes
occur in less than half the patients. We evaluate the pharmacokinetics in a patient with
elevated liver enzyme levels after liver transplantation, who received caspofungin for
the treatment of aspergillosis. Plasma concentrations of caspofungin were monitored at
2 different dosage regimens. The area under the concentration-time curve (AUC) at a
dosage of 70 mg was 191 mg*hr/L and was associated with an increase in liver enzymes.
After dose reduction to 50 mg with an AUC of 100 mg*hr/L, liver enzymes normalized.
In conclusion, caspofungin plasma concentrations may be helpful to evaluate exposure
and reduce the need for off-label dosing.
7.1 Introduction
I
nvasive aspergillosis (IA) is a rapidly progressive disease and an important cause
of morbidity and mortality in immunocompromised patients [1,2]. The guideline
of the Infectious Diseases Society of America for the treatment of IA recommends
the use of voriconazole as primary therapy. In patients who are refractory to or
intolerant of voriconazole, a lipid formulation of amphotericin B or caspofungin
can be used. The currently recommended dosage regimen of caspofungin in adults
with a body weight≤ 80 kg consists of an intravenous loading dose of 70 mg on day
1, followed by a daily maintenance dose of 50 mg. Although this dosage regimen
was developed for patients with invasive candidiasis (IC) [3], it is evaluated for the
treatment of IA. These studies have shown a favourable response of 33-42% [4, 5].
Caspofungin is concentration-independent and highly bound to plasma proteins.
The unbound fraction in plasma varies from 3.5% in healthy volunteers to 7.6% in
patients with IC [6, 7]. Caspofungin is generally well tolerated; the most frequently




A 60-year-old woman (weight: 65 kg) was admitted to our hospital for liver
transplantation. Tacrolimus and mycophenolic acid were administered as immuno-
suppressive therapy. Alkaline phosphatase (ALP) concentration was 180 IU/L (nor-
mal < 120 IU/L), aspartate aminotransferase (AST) concentration was 205 IU/L
(normal < 40 IU/L), alanine aminotransferase (ALT) concentration was 258 IU/L
(normal < 45 IU/L), and gamma-glutamyl transpeptidase (GGT) was 66 IU/L (nor-
mal< 40 IU/L) on day 6 after transplantation. Albumin concentration was 2.2 g/dL
(normal 3.5-5.5 g/dL) and the Child-Pugh score (CPS) was 9.
Four days after the transplantation, the patient suffered from respiratory insuffi-
ciency and was intubated. Six days after transplantation, Aspergillus fumigatus sus-
ceptible to voriconazole and amphotericin B was isolated from sputum. In addition,
the thoracic computed tomography scan showed several lesions distinctive for pul-
monary IA and the patient was diagnosed with probable IA.
Voriconazole was started in an intravenous loading dose of 6 mg/kg twice daily
followed by a reduced dose of 3 mg/kg twice daily, because liver enzyme levels
were elevated. On day 27 after the transplantation, liver enzymes were still ele-
vated, ALP was 329 IU/L, AST 40 IU/L, ALT 19 IU/L, and GGT 612 IU/L. Further-
more, the trough concentration of voriconazole (0.2 mg/L) was subtherapeutic and
therefore therapy was switched to caspofungin. Amphotericin B was considered
not suitable for this patient because of her estimated glomerular filtration rate of 34
mL/min.
With the intent of maximizing the potential effectiveness and with the known
safety at higher dosages described in the literature [8–11], a daily dose of 70 mg
caspofungin was chosen. With existing moderate increase in liver enzyme levels,
plasma concentrations of caspofungin were assessed on day 5 of therapy by a vali-
dated HPLC fluorescence detection method at the department of Clinical Pharmacy,
Nijmegen. The 24-h area under the concentration-time curve (AUC), which was
calculated based on the linear-log-trapezoidal rule, was 191 mg*hr/L (Fig. 7.1).
Notably, it is the unbound fraction that exhibits pharmacologic effects. There-
fore, the free drug AUC (fAUC) was calculated. Considering an unbound fraction of
7.6%, the fAUC was 14.5 mg*hr/L. The minimum inhibitory concentration (MIC) of
the Aspergillus fumigatus isolated from our patient was 0.05 mg/L, which is similar to
MICs described in the literature [12]. The above resulted in a calculated fAUC/MIC
ratio of 290.
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Figure 7.1: The 24-h area under the concentration-time curve of caspofungin with a dosage
of 70 mg and 50 mg/day.
Considering the severity of the infection and the good tolerability of caspofungin
by our patient, we decided to maintain the dosage at 70 mg/day. Afterwards, the
ALP concentration further increased to 605 IU/L, AST was 33 IU/L, ALT 30 IU/L,
and GGT 483 IU/L on day 39 after transplantation. No other hepatoxic medication
was given to the patient, nor was new medication introduced at this time. No clin-
ical symptoms of cholestasis or other liver disease were present and were therefore
excluded as underlying causes of the elevated liver enzymes.
The dosage of caspofungin was decreased to 50 mg/day and, in the following
days, the ALP concentration decreased to 175 IU/L, AST to 25 IU/L, AST to 14 IU/L,
and GGT to 79 IU/L. At steady state, plasma concentrations of caspofungin were
measured. The calculated AUC was 100 mg*hr/L (Fig. 7.1) and the corresponding
fAUC was 7.6 mg*hr/L, which resulted in a fAUC/MIC ratio of 152. Treatment
with caspofungin was continued in a dosage of 50 mg/day and liver enzyme levels
remained stable since the time of the last measurement.
After a total of 7.5 weeks of caspofungin treatment, the patient was mobilized
for upcoming discharge. The antifungal treatment at discharge was continued with
voriconazole orally, as liver function had normalized [1].
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7.3 Discussion
We described a case of IA treated with caspofungin at 2 different dosage regi-
mens. Although caspofungin is proven to be an effective antifungal agent in the
treatment of IA, successful outcomes occur in less than half the patients receiv-
ing caspofungin in the currently recommended dosage regimen [4, 5, 13]. Further-
more, the tolerance of caspofungin at higher dosages has been studied. The use
of caspofungin in a dosage of 70-150 mg/day in patients with IC and IA was well
tolerated and the incidence of drug-related adverse events was similar between the
standard and high-dose regimens. No serious drug-related adverse events or dis-
continuations of the study therapy because of drug-related adverse events were re-
ported [8–11]. Considering the severity of the infection, the reported response rate,
and the encouraging safety experience at higher dosages, a dose of 70 mg caspofun-
gin per day was chosen with the aim of maximizing the effectiveness of the treat-
ment.
However, 2 weeks after the start of the caspofungin treatment, the ALP concen-
tration further increased and GGT remained elevated. No interacting or hepatotoxic
comedication was used and no clinical symptoms of cholestasis or other liver dis-
ease were present.
Elevation in liver enzyme levels has been reported as a side effect of caspofun-
gin [1, 2]. The use of a higher dosage of caspofungin than recommended may have
contributed to the hepatotoxicity in our patient. Patients with a CPS of 7-9 should
receive a maintenance dosage of caspofungin of 35 mg/day [12, 14]. For reasons
mentioned earlier, together with the intolerance of the primary antifungal therapy,
the dosage of caspofungin was decreased from 70 to 50 mg instead of 35 mg/day.
After adjusting the dosage of caspofungin to 50 mg, liver enzyme levels decreased
and remained stable.
The fAUC/MIC was calculated during both dosage regimens. In vivo pharma-
codynamic studies have demonstrated that the AUC/MIC ratio is a good indica-
tor of the caspofungin exposure-response relationship [15]. A mean fAUC/MIC
associated with the stasis endpoint for caspofungin of 22 for Candida albicans was
found [15]. The fAUC/MIC ratio in our patient was far above this stasis end-
point in both dosage regimens. Nevertheless, caspofungin has a fungicidal activity
against Candida species and a fungistatic activity against Aspergillus [12]. The target
fAUC/MIC for caspofungin in the treatment of IA could be different from that for
IC and has yet to be established.
The calculated AUC at the dosage of 70 mg (191 mg*hr/L) in our patient was
higher than the AUC established in healthy volunteers at similar dosage (130-144
mg*hr/L) [16]. The AUC at the dosage of 50 mg (100 mg*hr/L) in our patient corre-
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sponded with the AUC measured in healthy volunteers (87-108 mg*hr/L) [15–17].
A similar exposure (116 mg*hr/L) is reached in patients with a CPS of 7-9 who re-
ceived a dosage of 35 mg [17]. If our patient had received a dose of 35 mg, the
exposure would probably have been lower than could have been expected based on
the results from that study. Therefore, 50 mg could be preferred over 35 mg in this
case.
When comparing both dosage regimens in our patient, the decline in AUC of
almost 50% after the dosage of caspofungin was decreased from 70 to 50 mg/day
is notable. We hypothesise that 2 factors may have contributed to the increased
AUC at 70 mg: a slight nonlinear pharmacokinetic behaviour [16], and the decreased
clearance caused by hepatic insufficiency [14].
7.4 Conclusion
In conclusion, the empirical choice for a higher dosage of caspofungin may have
resulted in hepatotoxicity in a patient with already elevated liver enzyme levels.
A dosage of 50 mg/day would probably have been safer. Furthermore, no evi-
dence yet available displays an improved effectiveness at higher dosages. Based
on our findings, we recommend monitoring for side effects when a higher dosage
of caspofungin than currently recommended is administered. Caspofungin plasma
concentrations may be helpful to evaluate exposure and reduce the need for off-label
dosing. More clinical studies in specific populations are necessary to examine the in-
fluence of patient characteristics on the pharmacokinetics and pharmacodynamics,
and thereby on the effectiveness and tolerability of caspofungin treatment.
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Chapter 8
The exposure and optimal dose of
caspofungin in critically ill patients
Abstract
Background: Echinocandins, such as caspofungin, are recommended as primary ther-
apy for invasive candidiasis (IC) in critically ill patients. The inter- and intra-individual
variability in caspofungin trough concentration appears to be high in patients in the
Intensive Care Unit (ICU).
Methods: A multicenter prospective intervention study in patients with (suspected) IC
was conducted at the ICU departments of 2 hospitals in the Netherlands, from November
2013 to December 2014. Patients received caspofungin according to the Summary of
Product Characteristics and the exposure was determined on day 3 of treatment. The
area under the concentration-time curve (AUC) over 24 hours was used as a measure
of the exposure, where an AUC of 98 mg*h/L was established as an adequate exposure.
In case of reduced exposure (i.e. ≥ 20% reduction in AUC), the caspofungin dose was
increased and the exposure was re-evaluated.
Results: By the time of this interim analysis, 10 patients were included in the study.
The median initial caspofungin AUC was 72.9 mg*h/L (interquartile range, 66.3 to 87.1
mg*h/L). The AUC was > 20% below 98 mg*h/L in 6 out of 10 patients. Multiple
linear regression analysis showed a positive association of the caspofungin AUC with the
caspofungin dose (mg/kg/day) (P = 0.007) and the albumin concentration (P = 0.079).
Conclusions: The AUC of caspofungin in ICU patients in this study was low compared
with healthy volunteers and other (non-) critically ill patients. Further research is needed




nvasive candidiasis (IC) is an important cause of morbidity and mortality in im-
munocompromised and critically ill patients. Patients in intensive care units (ICU)
are especially at risk of IC due to the presence of risk factors, such as the use of
a central venous catheter, parental nutrition, renal failure, mechanical ventilation,
previous broad spectrum antibiotic therapy, immunosuppression, neutropenia, or a
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recent major surgery [1,2]. IC occurs in approximately 10% of the ICU patients, rep-
resenting up to 15% of all nosocomial infections [1]. A crude mortality of 31 to 61%
is found in adult patients with IC, and IC is associated with a prolonged hospital
stay and increased costs [3–7].
Prompt initiation of effective antifungal therapy in the appropriate dosage is
required to improve outcome in patients with IC [8, 9]. The Infectious Diseases So-
ciety of America (IDSA) and the European Society for Clinical Microbiology and
Infectious Diseases (ESCMID) guidelines for the management of candidiasis recom-
mend the use of an echinocandin, such as caspofungin, as primary therapy for IC
in critically ill patients [10, 11]. In healthy volunteers receiving the standard dose
of caspofungin, the mean area under the concentration-time curve (AUC) over 24
hours was 98 (88-108) mg*hr/L [12–14]. In critically ill patients, the pharmacoki-
netics and hence the plasma concentration of a drug may be influenced by altered
drug distribution and clearance [15–19]. Inter- and intra-individual variability in
caspofungin trough concentration appeared to be high in ICU patients [20]. Fac-
tors that were associated with low caspofungin plasma concentrations were body
weight > 75 kg and hypoalbuminemia, which is present in up to 60% of the ICU pa-
tients [20, 21]. Capillary permeability, third spacing, and multi organ failure may
also influence the caspofungin concentration in ICU patients [10]. Furthermore,
plasma concentrations of caspofungin might be influenced by disease severity [8,9].
The primary objective of this study was to determine the optimal dose of caspo-
fungin in relation to adequate exposure in critically ill patients. Secondary objectives
were to establish the pharmacokinetic parameters of caspofungin in critically ill pa-




This multicenter prospective intervention study was conducted at the 46-bed
ICU department of the University Medical Center Groningen, and the 18-bed ICU
department of the Medisch Spectrum Twente, the Netherlands, from November
2013 to December 2014. Patients were eligible for inclusion if the following criteria
were met: (1) age ≥ 18 years, (2) admission to the ICU department, (3) (suspected)
invasive candidiasis, and (4) treatment with caspofungin. Patients were excluded if
they did not have a central venous line for blood sampling. The local ethics commit-
tee approved the study (Institutional Review Board protocol no. 2012-371) and the
study was registered at ClinicalTrials.gov (NCT 01994096). Written informed con-
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sent was obtained from the patient or the legal representative of the patient before
any study-related procedures were performed.
Caspofungin was administered once daily by intravenous infusion over 1 hour
according to the Summary of Product Characteristics (SPC) of caspofungin [22]. The
recommended dose regimen of caspofungin consists of an intravenous loading dose
of 70 mg on day 1, followed by a daily maintenance dose of 50 mg for patients ≤ 80
kg and 70 mg for patients > 80 kg. In patients with impaired hepatic clearance, a
dose reduction to 35 mg per day is recommended [22]. Steady state of caspofungin
is reached on the first day after the loading dose [14]. On day 3 (± 1 day), blood
samples were taken just before administration of caspofungin and 1, 2, 3, 4, 6, 8, 12,
and 24 hours after the start of the infusion, to determine the AUC over 24 hours in
steady state and other pharmacokinetic parameters of caspofungin. The AUC was
used as a measure for the exposure, where an AUC of 98 mg*h/L was established
as an adequate exposure [12–14]. An AUC value below 79 mg*h/L (i.e. ≥ 20%
reduction) was considered as a clinically relevant reduced exposure [22, 23] and in
this case the caspofungin dose was increased. In case of a decline in AUC of 20
to 40% the dose was increased with 40%, and in case of a decline in AUC > 40%,
the caspofungin dose was doubled. If the caspofungin dose was adjusted, the AUC
was determined on day 3 (± 1 day) after dose adjustment. When the patient was
on an adequate dose regimen, trough levels were followed every 3 days during
treatment on the ICU, with a maximum of 28 days, to evaluate potential fluctuations
in caspofungin concentration over time. Mortality was assessed at day 28 after the
start of the caspofungin treatment.
8.2.2 Data collection
Caspofungin plasma concentrations were determined within 24 hours, using a
validated liquid chromatography-tandem mass spectrometry assay [24]. Non com-
partmental analysis (KINFIT, MWPharm 3.60, Mediware, the Netherlands [25]) was
used to calculate the pharmacokinetic parameters, including the clearance (CL),
volume of distribution (Vd), half life (t1/2), and the AUC over 24 hours, which
was calculated using the log-linear trapezoidal rule. Patient data were collected
through review of the medical records using a standardized case report form. De-
mographic and clinical data were collected including age, race, sex, weight, un-
derlying condition, reason for ICU admission, presence of renal replacement ther-
apy, Candida species, site of infection, and the Candida score [26]. Vital signs (tem-
perature, blood pressure, heart rate, respiratory rate, oxygenation) and laboratory
parameters (leukocyte count, C-reactive protein, albumin, bilirubin, alkaline phos-
phatase, aspartate aminotransaminase (ASAT), alanine aminotransaminase (ALAT),
γ-glutamyl transpeptidase, serum electrolytes, serum urea, and serum creatinine
108 Chapter 8
concentration) were routinely measured on the ICU. Disease severity scores were
calculated on the day the first AUC of caspofungin was obtained, including the
acute physiology and chronic health evaluation (APACHE II [27] and APACHE
IV [28]), the simplified acute physiology score (SAPS 3 [29]), and the sepsis-related
organ failure assessment (SOFA [30]). Medical data were recorded on caspofungin
dose adjustments, duration of treatment with caspofungin, and comedication. Sus-
pected adverse events were reported, in accordance with Good Clinical Practice,
and a potential causal relationship with the use of caspofungin was established by
the physician of the patient and the local investigator using the Naranjo adverse
drug reaction probability scale [31].
8.2.3 Statistical analysis
For the univariate analysis, a Spearman correlation coefficient was calculated to
determine correlations between 2 continuous variables. For comparing 2 or more
groups, the Mann-Whitney U test and Kruskal-Wallis test were used. We assessed
the correlation of the caspofungin AUC with the caspofungin dose (mg/kg/day)
and with factors that can influence the pharmacokinetics of caspofungin, such as
the patients age, weight, liver test results, albumin concentration, and with disease
severity scores. Furthermore, we compared the caspofungin AUC between patient
groups with different sex, race, the presence of dialysis, and interacting comedi-
cation. To assess the relationship between the caspofungin exposure and several
explanatory variables, variables with a P-value of < 0.10 from the univariate anal-
ysis and variables that potentially can influence the caspofungin exposure were in-
cluded in the multiple linear regression analysis. Multiple linear regression analysis,
with the AUC of caspofungin as dependent variable, was performed with backward
analysis, thereby removing non-significant variables, starting with the one with the
highest P value. All statistical analyses were performed using SPSS for Windows,
version 22.0 (IBM SPSS, Chicago, Illinois). A P value < 0.05 was considered statisti-
cally significant.
8.3 Results
By the time of this interim analysis, 10 patients were included in the study and
their medical records were reviewed. The mean age of the patients was 53 years
(range, 25 - 83 years), 6 patients were male and 7 patients were Caucasian. The pa-
tients‘ characteristics are shown in Table 8.1. The mean stay on the ICU was 18.1
days (range 4 - 42 days), and 5 patients received continuous veno-venous hemofil-
tration (CVVH). The mean APACHE II was 19 (range, 9 - 32), the mean APACHE
IV was 102.4 (range, 62 - 135), the mean SAPS 3 was 58.1 (range, 31 - 74), and the
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mean SOFA was 9.1 (range, 3 - 14). Two patients had candidemia and 8 patients
had suspected invasive candidiasis based on culture results in abdominal fluid in
2 patients, pus in a closed space in 2 patients, sputum in 2 patients, and in pleural
fluid and a central venous catheter tip in 1 patient each. The causative pathogen
was Candida albicans in 7 patients, followed by C. glabrata in 2 patients, and a yeast
not specified in 1 patient. The mean candida score was 2.7 (range, 1.8 - 4.0).
The mean duration of treatment with caspofungin was 6.9 days (range, 3 - 15
days). Four patients received hydrocortisone, 2 patients received prednisolone, 1
patient received efavirenz, 1 patient received tacrolimus and mycophenolate, and
1 patient received fluconazole as comedication. Caspofungin was discontinued be-
cause empirical treatment was no longer indicated in 4 patients, antifungal treat-
ment was continued with fluconazole due to a cultured C. albicans sensitive to flu-
conazole in 3 patients, switch to amphotericin B in 2 patients (1 patient lack of effi-
cacy, 1 patient possible retinal involvement), and because 1 patient died. At day 28
after the start of the treatment with caspofungin, 1 patient was deceased. Liver en-
zymes increased in 3 patients during treatment with caspofungin. According to the
Naranjo adverse drug reaction probability scale there was a possible relation with
the use of caspofungin (score of 2 out of 13 for all 3 patients).
8.3.1 Caspofungin pharmacokinetics and exposure
The pharmacokinetic parameters of caspofungin on day 3 of the treatment are
shown in Table 8.2. The initial median AUC over 24 hours of caspofungin was 72.9
mg*h/L (interquartile range [IQR], 66.3 - 87.1 mg*h/L). The mean plasma concentra-
tion-time curve is shown in Figure 8.1. The caspofungin AUC showed the best as-
sociation with the caspofungin concentration 8 hours after the start of the infusion
(correlation coefficient 0.954; P < 0.001) and 12 hours after the start of the infusion
(correlation coefficient 0.953; P < 0.001). The correlation coefficient of the AUC with
the trough concentration (24 hours after the start of the infusion) was 0.839; P <
0.001. When patients were on an adequate dose regimen, caspofungin trough con-
centrations were determined (in 5 patients) and were stable over time.
The AUC was > 20% below 98 mg*h/L in 6 patients (Table 8.1). Two of these
patients received a caspofungin dose of 35 mg per day due to severe liver failure
or liver cirrhosis. In 3 of the 6 patients, the caspofungin dose was increased with
40% where after the exposure was adequate. In the other 3 patients, caspofungin
was discontinued before the second AUC could be determined. The AUC of caspo-
fungin showed no significant correlation with the patients‘ age, weight, liver test
results, albumin concentration, caspofungin dose, and disease severity scores. Fur-
thermore, the caspofungin AUC was not significantly different in patients with dif-




















































































































































































































































































































0 4 8 12 16 20 24
Figure 8.1: Caspofungin concentration-time curve on day 3 of the treatment (mean with stan-
dard deviation).
linear regression analysis, variables obtained by the univariate analysis (caspofun-
gin dose (mg/kg/day), ASAT, ALAT) and variables that can theoretically indicate
altered pharmacokinetics (albumin concentration [20]) were included. The multiple
linear regression analysis showed a significant and positive association of the ini-
tial caspofungin AUC with the caspofungin dose (mg/kg/day) (effect 93.533 (95%
confidence interval [CI], 35.386 - 151.680), P = 0.007) and the albumin concentration
(effect 1.729 (95% CI, –0.261 - 3.719); P = 0.079).
8.4 Discussion
The median AUC of caspofungin found in this study was 72.9 mg*h/L. The AUC
was low compared to the AUC of 98 (88 - 108) mg*hr/L established in healthy vol-
unteers [12–14], an AUC of 110 - 117 mg*hr/L found in non-critically ill patients [32],
and an AUC of 88.7 mg*hr/L (IQR, 72.2 - 97.5 mg*h/L) recently established in ICU
patients [33]. The Vd was larger and the Cmax of caspofungin was lower compared
to healthy volunteers and patients in other studies [13,14,32,33]. The t1/2 was com-
parable to the t1/2 in other ICU patients [33] and was longer than the t1/2 in healthy
volunteers [13,14]. The low AUC of caspofungin in our study is therefore most likely
the result of a larger Vd. Fluid extravasation as a result of endothelial dysfunction
and capillary leak, edema in sepsis, ascites, fluid resuscitation, and hypoalbumine-
mia are factors that are often present in ICU patient and can all lead to an enlarged
112 Chapter 8
Table 8.2: Pharmacokinetic parameters of caspofungin (n=10). Abbreviations: AUC0−24,
area under the concentration-time curve over 24 hours; Cmax, the maximal concentration;
Cmin, and minimal concentration; CL, clearance; IQR, interquartile range; Vd, volume of
distribution; t1/2, half life.
Parameter Median (IQR)
AUC0−24 (mg*h/L) 72.9 (66.3 - 87.1)
Cmin (mg/L) 1.7 (1.4 - 2.2)
Cmax (mg/L) 6.4 (6.0 - 7.5)
CL (L/h) 0.45 (0.29 - 0.52)
Vd (L) 10.01 (8.27 - 11.78)
t1/2 (h) 17.02 (14.54 - 20.30)
Vd and a lower drug concentration [16–18].
Multiple linear regression analysis showed that the initial caspofungin AUC was
significantly associated with the caspofungin dose in mg/kg/day. Furthermore, the
3 patients between 75 and 80 kg who received a dose of 50 mg, according to the
SPC of caspofungin, all had AUCs (> 20%) below the AUC of 98 mg*h/L, the es-
tablished set-point for adequate exposure. If this finding can be confirmed in subse-
quent study participants, this could indicate that the currently used cut-off value
of > 80 kg for a higher maintenance dose of 70 mg may be too high and more
patients should receive the higher maintenance dose of 70 mg once daily. Caspo-
fungin has shown good tolerability at higher doses. The use of caspofungin in a
dose of 70 to 200 mg per day was well tolerated and the incidence of drug-related
adverse events was similar between the standard and high-dose regimens [34–38].
Furthermore, a positive correlation of the caspofungin AUC with the albumin con-
centration was found. Caspofungin is extensively bound to albumin [22] and hy-
poalbuminemia can lead to an increased drug Vd and an enhanced clearance of the
free drug [39]. The association with both weight and albumin concentration was in
agreement with an earlier study of caspofungin trough concentrations in ICU pa-
tients [20]. Although one study showed a lower response rate among patients with
a higher APACHE II [40], the AUC of caspofungin was not associated with disease
severity scores, which was in agreement with recent findings [33, 41].
Two patients in our study suffered from severe liver damage or cirrhosis and
received a daily caspofungin dose of 35 mg according to the SPC of caspofungin.
The AUC was low in both patients and the dose was increased to 50 mg, after which
liver enzymes remained stable. This finding is in accordance with two case reports
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where 50 and 70 mg was given to patients with moderate hepatic dysfunction and
where the exposure was similar to the exposure in healthy volunteers [42,43]. These
findings illustrate the fact that at the bed site, liver drug metabolism may be under-
estimated in the presence of liver test abnormalities or evidence of cirrhosis. Com-
bined with the case reports, our findings suggest that these patients should perhaps
initially receive an empiric maintenance dose of 50 mg per day instead of 35 mg,
with close follow-up with therapeutic drug monitoring (TDM) and monitoring of
liver enzymes. Further research in this patient group is needed to provide evidence
for the development of new dosing recommendations.
A limitation of this study is the small number of patients. However, the study is
ongoing and more patients will be included to obtain a more reliable result. Further-
more, the minimal inhibitory concentration (MIC) of the Candida species was only
determined in 1 patient. Since most patients had suspected IC based on culture data
from non-sterile sites, the MIC of the Candida species was not determined in these
patients. In vivo studies have demonstrated that the AUC/MIC is a good descrip-
tor of the echinocandin exposure-response relationship. For caspofungin an AUC0-
24h/MIC of 865 was established for a 1 log kill of C. albicans and an AUC0-24h/MIC
of 450 for a 1 log kill of C. glabrata [12]. Considering the AUC of approximately 100
mg*h/L, the AUC/MIC target can be reached when C. albicans species have MIC
values ≤ 0.125 and C. glabrata have MIC values ≤ 0.25. The median AUC of the pa-
tients in this study was lower, however, in case of low MIC values, the AUC/MIC
can still be sufficient with lower AUC values.
Since 60% of the patients had a low caspofungin exposure, TDM can be of added
value for the treatment with caspofungin in ICU patients. TDM can help to ensure
timely target attainment of caspofungin in these patients. Since the crude mortality
is still up to 61% in critically ill patients with IC, we believe that TDM is a powerful
tool to optimize the antifungal treatment with caspofungin. A prospective random-
ized clinical trial should be carried out to determine if therapeutic interventions, to
increase the caspofungin exposure, result in an improved treatment outcome.
8.5 Conclusion
In conclusion, the AUC of caspofungin in ICU patients in this study was low
compared with healthy volunteers and other (non-) critically ill patients. The caspo-
fungin AUC was significantly associated with the caspofungin dose (mg/kg/day)
and with the albumin concentration.
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Chapter 9
General discussion & future perspectives
I
n this thesis we have evaluated the pharmacokinetics and the exposure of anti-
fungal drugs in critically ill adults and children. We have shown that insufficient
antifungal drug exposure is common in critically ill patients and that the standard
dose, recommended in the Summary of Product Characteristics, is often inadequate
for this patient group.
9.1 Critically ill pediatric patients
In Chapter 2 we have shown that pediatric cancer patients do not achieve an ade-
quate exposure to fluconazole with the currently recommended dosing regimen and
that a higher fluconazole concentration was associated with a shorter time to culture
conversion [1]. Over the past 5.5 years, Candida species were cultured in 1248 chil-
dren in the University Medical Center Groningen. In 94% of the cases, the Candida
isolate was susceptible to fluconazole. The average costs for intravenous treatment
with fluconazole were e 28 per patient per day (2014). If the treatment with flu-
conazole fails, more expensive second line antifungal agents, such as amphotericin
B (e 145 - e 290 per day) or caspofungin (e 420 per day), are used for the treatment
of invasive candidiasis (IC). With the determination of an optimal fluconazole dose,
an adequate treatment with fluconazole can be achieved and hence there is no need
to divert to more expensive second line antifungal agents. Furthermore, mortality
significantly increases in patients with candidemia if there is a delay in the initiation
of adequate fluconazole therapy, and an inadequate fluconazole dose is associated
with an increased hospital stay and costs [2, 3]. Adequate exposure to fluconazole
is therefore essential for an effective treatment and hence for a better outcome of
the treatment, potentially leading to a reduced hospital stay. A prospective dose-
finding study of fluconazole in pediatric cancer patients should be carried out to
determine a more appropriate fluconazole dose and to ensure adequate fluconazole
exposure in these patients. Fluconazole is a powerful and cheap drug and it is the
primary therapy in children with IC. Provided that dose adjustments are made for
specific patient groups, such as cancer patients, fluconazole is still a good choice for
the treatment of IC in children and infants.
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In Chapter 2 we have shown that it is important to evaluate the treatment with
antifungal drugs in children. Children are typically not included in registration
studies by the manufacturer of the drug due to ethical problems and technical chal-
lenges. As a result, many drugs have not been approved for the use in children, and
drugs are often used outside the terms of the product‘s approval (off-label use). In-
deed, almost half of the drugs prescribed in a children‘s hospital in the Netherlands
were unapproved for the use in children [4]. Since children clearly need the treat-
ment, the recommended childrens dose is extrapolated from the adult dose, which
may result in decreased efficacy or toxic effects. To overcome the above-mentioned
challenges, observational studies could be very useful to evaluate the drug exposure
and to collect data on the treatment when (new) drugs are administered to children.
Based on the collected data, the treatment can be optimized and childrens dosing
recommendations could be made without extensive clinical trials. Besides, with
the development of noninvasive sampling methods, such as oral fluid and dried
blood spot (DBS) analysis, pharmacokinetic studies and Therapeutic Drug Moni-
toring (TDM) are much less burdening, and can therefore easier be performed in
children.
9.2 Patients on the intensive care unit
In critically ill adults, the echinocandins (such as caspofungin) are recommended
as primary therapy for IC. Furthermore, caspofungin is recommended as empirical
treatment for suspected IC in this patient population [5]. In Chapter 8, we have
shown that the caspofungin exposure in patients on the intensive care unit (ICU)
was low compared with the exposure in healthy volunteers and other (non-) criti-
cally ill patients, most likely as a result of a larger volume of distribution. Further-
more, the exposure was low in patients of certain weight categories and in patients
suffering from severe liver damage who received a reduced caspofungin dose. Our
findings suggest that these patients should perhaps initially receive a higher empiric
maintenance dose. Since a delay in empirical treatment is a potential risk factor for
mortality [6], it is important to provide early appropriate treatment and to achieve
adequate exposure early after the start of the treatment. Our findings, as well as pre-
viously published case reports [7,8], were all in ICU patients and these findings have
not yet been confirmed in other patient groups, such as patients with hematological
malignancies. Further research is needed to provide evidence for the development
of new dosing recommendations. With these dosing recommendations, and sub-
sequent TDM in certain cases, adequate exposure can be achieved shortly after the
start of the treatment with caspofungin in ICU patients.
Our study showed that it is important to perform pharmacokinetic studies and
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to evaluate the exposure of drugs in critically ill patients since the pharmacokinetics
and hence the plasma concentration of a drug can be influenced by altered drug ab-
sorption, distribution, metabolism, and clearance in this patient group [9–14]. Since
most patients on the ICU have a central venous catheter, blood sampling to obtain
full pharmacokinetic curves can relatively easy be performed in these patients. It
is important to start observational pharmacokinetic studies as soon as new drugs
are introduced in this patient group. If the exposure appears insufficient, prospec-
tive dose finding studies should be performed to develop more appropriate dosing
regimens for patients on the ICU.
9.3 Immunocompromised patients
In Chapter 4 we have demonstrated that the posaconazole exposure was not suf-
ficient in over 40% of patients with invasive fungal disease (IFD), or those at risk for
IFD, after administration of the oral suspension. Furthermore, a higher posacona-
zole concentration was associated with improved outcome. Based on the results of
our study and other recent findings, we recommend that the posaconazole oral sus-
pension is not prescribed to patients who are unable to eat or use a proton pump
inhibitor/H2-antagonist [15–22]. The gastro-resistant tablet or the intravenous for-
mulation that has recently entered the market, are more suitable for these patients.
An adequate exposure is reached with both formulations in a once daily dose com-
pared to the oral suspension, which requires dosing between two and four times
daily [23–26]. Since the tablet cannot be crushed or chewed, the oral suspension
will remain a treatment option for patients who are unable to take tablets. Posa-
conazole is used as salvage therapy for invasive aspergillosis, with only few other
alternatives left, and it is used for the treatment of specific and life threatening IFD,
such as zygomycosis [27, 28]. Optimizing the posaconazole exposure in these pa-
tients is important for survival. Besides, posaconazole has been associated with
an improved safety profile compared to voriconazole and concentration-dependent
adverse events have not been identified to date [24]. The different posaconazole
formulations, in combination with TDM in case of the oral suspension [29, 30], can
help to ensure sufficient posaconazole exposure and these factors taken together
make posaconazole a valuable addition to the antifungal prophylaxis and treatment
arsenal.
9.4 Therapeutic Drug Monitoring
Critically ill patients often have complex and multiple pathologies while they
receive multiple pharmacotherapeutic and other interventions. The pharmacoki-
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netics of antifungal drugs can therefore be influenced and unpredictable and the
required antifungal drug exposure may not be reached. Besides the development
of new dosing strategies for critically ill patients, TDM can be useful to ensure that
patients achieve target drug concentrations while toxicity is prevented [9, 10]. TDM
of voriconazole, posaconazole, itraconazole, and flucytosine may improve treatment
outcome with reduced toxicity; TDM is therefore recommended in the guidelines for
the treatment of IFD [5,29,31–37]. For fluconazole and caspofungin, TDM may have
added value for the treatment. TDM can help to ensure timely target attainment in
critically ill (pediatric) patients who are at risk of under-exposure. Preferably, new
dosing recommendations should be developed for these patients, reducing the need
for TDM. However, TDM remains important in critically ill adults and children who
do not respond adequately to the antifungal therapy, who have infections at sanctu-
ary sites (e.g. central nervous system), who have an infection with an organism with
a reduced susceptibility, in patients with disease carrying a poor prognosis, in case
of drug-drug interactions; and if toxicity is suspected [30, 38]. Prospective random-
ized clinical trials should be carried out to determine if therapeutic interventions
aiming at optimizing drug exposure, result in an improved treatment outcome.
To facilitate TDM of antifungal drugs, we have developed noninvasive sampling
methods for performing TDM, such as an oral fluid analysis for fluconazole in pedi-
atric patients (Chapter 3) and a DBS analysis for the azoles in adult patients (Chap-
ter 5) [39, 40]. Oral fluid sampling is a noninvasive, painless alternative to perform
TDM in children when blood sampling is not possible or desirable and it is preferred
over blood sampling by the majority of the patients and their parents [41]. DBS was
advantageous in that sampling was significantly less painful, and DBS can be per-
formed at home, saving time traveling to the hospital for blood sampling [40]. With
oral fluid and DBS analysis, the possibilities of TDM of the triazoles can be extended
to patients at home and to hospitals without an advanced bioanalytical infrastruc-
ture. Furthermore, these methods can be used in research in children and adults
where venous blood sampling is not possible or not desirable.
9.5 Therapeutic drug management
To ensure adequate treatment, the exposure of the antifungal drug needs to be
sufficient. Besides the exposure, the susceptibility of the organism is equally im-
portant to reach the required pharmacokinetic and pharmacodynamic (PK/PD) tar-
get. In vivo studies have demonstrated that the area under the concentration-time
curve (AUC) over 24 hours to the minimum inhibitory concentration (MIC) is a
good descriptor of the fluconazole and echinocandin exposure-response relation-
ship [42–44]. Our studies showed that the antifungal drug exposure in critically
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ill patients was low, however, if MIC values are low as well, the AUC/MIC target
can still be reached with lower AUC values. It is therefore important to know the
AUC/MIC, not only to establish adequate exposure, but also to avoid unnecessary
dose escalations, thereby avoiding possible side effects. Furthermore, antifungal re-
sistance is increasing and infections with isolates with elevated MICs are associated
with poorer outcomes and breakthrough infections during antifungal treatment and
prophylaxis [36, 45–47]. Antifungal drug susceptibility testing is therefore an essen-
tial component to guide therapeutic decision-making and to optimize the antifungal
treatment while reducing the emergence of antifungal resistance.
9.6 Final remarks
With the increasing number of immunocompromised and critically patients, the
incidence of IFD such as candidemia and invasive aspergillosis has increased in
recent years [48]. Antifungal treatment has improved survival in these patients,
however, mortality due to IFD has remained high with the currently used antifungal
dosing regimens [33, 49–60]. Too often, the antifungal drug exposure in critically ill
adults and children is inadequate with the standard dose. These findings call for the
development of a more personalized therapy for patients with IFD. This treatment
should be based on the characteristics of the fungus (type, MIC, location) and on
the characteristics of the patient (underlying disease, and treatment of the disease,
leading to altered absorption, distribution, metabolism, or clearance of the drug).
Together, the characteristics of the fungus and the patient provide information on
the appropriate antifungal treatment for the individual patient in the optimal dose,
thereby avoiding unnecessary, ineffective, or toxic therapy [61]. With this strategy,
adequate antifungal treatment can be achieved with the current arsenal of antifungal
drugs [62].
In conclusion, it is important to investigate the pharmacokinetics and exposure
of antifungal drugs in critically ill adults and children and establish the optimal
dose for these patient groups. Adequate initial dosing regimens and subsequent
TDM are needed to ensure a fast and adequate drug exposure and to attain the
required PK/PD target in the critically ill patient, resulting in an improved efficacy
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Summary
With the growing number of immunocompromised and critically ill patients,as the result of aggressive cancer treatment and immunosuppressive treat-
ment after organ and stem cell transplantation, the incidence of invasive fungal
disease (IFD) such as invasive candidiasis (IC) and invasive aspergillosis (IA) has
increased in recent years. In IC and IA, the fungus has entered the bloodstream and
has spread throughout the whole body. These IFD are important causes of morbidity
and mortality and are associated with a prolonged hospital stay and increased costs.
Prompt initiation of antifungal therapy in the appropriate dose is required to im-
prove outcome in patients with IFD. However, when drugs are registered, severely
ill patients are usually not included in registration studies by the manufacturer of
the drug. Hence it is often unknown if the recommended dose is also suitable for
this patient group, since the behavior of the drug in the body (pharmacokinetics)
and the blood concentration can be altered due to changes in absorption, distribu-
tion, metabolism, and clearance of the drug. The altered pharmacokinetics of drugs
also applies to critically ill children and infants. Moreover, developmental changes
in renal and hepatic function, the gastrointestinal tract, and body composition can
contribute to a varying drug concentration with age. Children are typically not in-
cluded in registration studies, due to ethical issues and technical challenges, and the
recommended childrens dose is therefore extrapolated from the adult dose, which
may result in decreased efficacy or toxic effects. In this thesis we have evaluated
the pharmacokinetic parameters and the exposure of antifungal drugs and estab-
lished the relation with the treatment outcome in critically ill adults and children.
Furthermore, we have developed noninvasive sampling methods to facilitate ther-
apeutic drug monitoring (monitoring of drug concentrations in blood/body fluids
and subsequent dose adjustments, TDM).
In Chapter 2, in a retrospective study we have evaluated the exposure of the
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antifungal drug fluconazole in 99 critically ill children. Besides, we have assessed
the relation between the fluconazole blood concentration and the time to attain a
negative culture (culture conversion). The study showed that the fluconazole con-
centration was considered subtherapeutic in 40% of the patients. The fluconazole
exposure was significantly lower in pediatric cancer patients, with the currently
recommended dosing regimen, compared to children with a different underlying
condition (P = 0.003). Furthermore, a higher fluconazole concentration was sig-
nificantly associated with a shorter time to culture conversion in these critically ill
children. Hence, pediatric cancer patients do not achieve an adequate fluconazole
exposure with the currently recommended dosing regimen and a higher flucona-
zole dose is required. We recommend the development of a new dosing strategy
to achieve adequate fluconazole exposure in pediatric cancer patients. In addition,
TDM of fluconazole can be a valuable tool to detect possible under-exposure in crit-
ically ill children. Children do often fear needles and can have difficult vascular
access. In Chapter 3 we have developed and clinically validated a method of anal-
ysis to determine fluconazole in 21 oral fluid samples from pediatric patients. The
fluconazole concentration in oral fluid was in good agreement with the blood con-
centration of fluconazole and samples were stable at room temperature for at least
17 days. Oral fluid sampling can be a noninvasive, painless alternative to perform
TDM of fluconazole in children when blood sampling is not possible or desirable.
When patients receive prolonged courses of antifungal treatment and use flucona-
zole at home, this method of analysis can extend the possibilities of TDM for patients
at home.
In Chapter 4, we have evaluated the posaconazole exposure in 70 adult cancer
patients and organ transplant recipients. We have detected risk factors for underex-
posure of posaconazole and assessed the relation between the posaconazole expo-
sure and the treatment outcome. The posaconazole exposure was not sufficient in
over 40% of patients with IFD, and those at risk for IFD, after administration of the
posaconazole oral suspension. Risk factors for underexposure were a lack of enteral
nutrition (patients who were not able to eat), a liquid diet, vomiting, use of med-
ication that affects the pH of the stomach (such as a proton pump inhibitor (PPI)
or H2-receptor antagonist), and concomitant chemotherapy. Furthermore, a higher
posaconazole concentration was significantly associated with a better treatment out-
come. Based on the results of our study and other recent findings, we recommend
that the posaconazole oral suspension is not prescribed to patients who are unable
to eat or use a PPI/H2-antagonist. With the new tablet and intravenous formulation,
posaconazole is also suitable for patients with no food intake, absorption problems,
and the use of concomitant medication that affects gastric pH. The different posaco-
nazole formulations, in combination with TDM in case of the oral suspension, can
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help to ensure sufficient posaconazole exposure and make posaconazole a valuable
addition to the antifungal prophylaxis and treatment arsenal. To facilitate TDM of
posaconazole and the other triazoles, we have developed and clinically validated
a dried blood spot (DBS) analysis, using a finger prick instead of a venous blood
sample in 28 patients (Chapter 5). DBS concentrations of posaconazole, fluconazole,
and voriconazole were in good agreement with plasma concentrations and samples
were stable at room temperature for at least 12 days. The majority of the patients
preferred DBS sampling over venous blood sampling. Major advantages of DBS
sampling were significantly less pain and not traveling to the hospital for blood
sampling. With this DBS analysis, the possibilities of TDM of the triazoles can be
extended to patients at home and to hospitals without an advanced bio-analytical
infrastructure.
For the determination of caspofungin concentrations, we developed a method of
analysis to measure caspofungin concentrations in blood in Chapter 6. Subsequently
in Chapter 8, we have evaluated the pharmacokinetics and exposure of caspofungin
in patients with (suspected) IC on the Intensive Care Unit (ICU) in a multicenter
prospective intervention study. The interim analysis of this study showed that the
caspofungin exposure in 10 ICU patients was low compared with the exposure in
healthy volunteers and other (non-) critically ill patients, most likely as a result of a
larger volume of distribution. Furthermore, the exposure was low in patients of 75
to 80 kg who received the standard dose of 50 mg (patients > 80 kg receive a stan-
dard dose of 70 mg) and in patients suffering from severe liver damage who received
a reduced caspofungin dose of 35 mg, which we previously also demonstrated in a
case report (Chapter 7). Our findings suggest that these patients should perhaps
initially receive a higher empiric maintenance dose. However, further research is
needed to provide evidence for the development of new dosing recommendations
for this patient group. With these dosing recommendations, and subsequent TDM
in certain cases, an adequate caspofungin exposure can be achieved shortly after the
start of the treatment with caspofungin in ICU patients.
In this thesis, we have shown that the antifungal drug exposure in critically ill
adults and children is often inadequate with the standard dose. Adequate exposure
is essential for efficacy, and ultimately, for improved outcome. Our findings call for
the development of a more personalized therapy for patients with IFD (chapter 9).
This treatment should be based on the characteristics of the fungus (type of fungus,
minimum concentration that inhibits the growth of the fungus, and location of the
infection) and on the characteristics of the patient (underlying disease and treatment
of the disease, leading to altered absorption, distribution, metabolism, or clearance
of the drug). Together these characteristics provide information on the appropriate
antifungal treatment for the individual patient, leading to an optimal drug exposure
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and avoiding unnecessary, ineffective, or toxic therapy. With this strategy, adequate
antifungal treatment can be achieved with the current arsenal of antifungal drugs.
Samenvatting
I
n de afgelopen jaren zijn bij de behandeling van kanker steeds agressievere mid-
delen ingezet met als gevolg een sterk verzwakt immuunsysteem van de patie¨nt.
Bovendien zorgt het toenemende aantal mogelijkheden op het gebied van orgaan-
en beenmergtransplantatie voor meer patie¨nten die geneesmiddelen gebruiken die
het immuunsysteem onderdrukken en zodoende afstoting van het transplantaat
proberen te voorkomen. Deze ernstig zieke patie¨nten lopen het risico op een levens-
bedreigende schimmelinfectie met een schimmel die doordringt in de bloedbaan
en de organen vanwege hun sterk verminderde afweer. De meest voorkomende
schimmelinfecties worden door Candida en Aspergillus veroorzaakt. Deze ernstige
schimmelinfecties zijn de laatste jaren toegenomen en zijn een belangrijke oorzaak
van sterfte bij deze verzwakte patie¨nten. Patie¨nten die een ernstige schimmelinfec-
tie hebben, liggen langer in het ziekenhuis en daardoor zijn de zorgkosten bij deze
patie¨nten ook hoger.
Een snelle start van antischimmeltherapie in de juiste dosering is nodig om het
resultaat van de behandeling te verbeteren. Wanneer geneesmiddelen op de markt
komen, worden ernstig zieke patie¨nten echter niet meegenomen in de registratie-
studies die door de fabrikant van het geneesmiddel worden uitgevoerd. Het is daar-
door niet altijd zeker of de dosering, die door de fabrikant wordt aanbevolen, ook
geschikt is voor deze patie¨ntengroep. De farmacokinetiek (het gedrag van een ge-
neesmiddel in het lichaam) en de concentratie van het geneesmiddel in het bloed
kunnen bij ernstig zieke patie¨nten afwijken van die van gezonde mensen. In deze
patie¨ntengroep kan de absorptie, verdeling, omzetting (metabolisme) en uitschei-
ding van een geneesmiddel zijn veranderd als gevolg van de onderliggende ziekte
of de behandeling van die ziekte. Ditzelfde geldt ook voor ernstig zieke kinderen en
baby’s. Baby’s en kinderen zijn daarnaast nog in de groei en veranderingen in nier-
en leverfunctie, maag-darmkanaal en water-vet verdeling in het lichaam kunnen er
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voor zorgen dat de concentratie van het geneesmiddel in het bloed varieert met de
leeftijd. Kinderen worden over het algemeen niet meegenomen in registratiestudies
vanwege ethische bezwaren en technische problemen. De aanbevolen kinderdose-
ring wordt daarom afgeleid van de dosering voor volwassenen. Dit kan resul-
teren in zowel een verminderde werkzaamheid van het geneesmiddel, of juist in
vergiftigingsverschijnselen. In dit proefschrift hebben we de farmacokinetiek en
de blootstelling aan antischimmelmiddelen gee¨valueerd en de relatie met het re-
sultaat van de behandeling vastgesteld in ernstig zieke volwassenen en kinderen.
Tevens hebben we methodes ontwikkeld om het uitvoeren van therapeutic drug
monitoring (het bepalen van de geneesmiddelconcentratie in bloed of een andere
lichaamsvloeistof waarmee de dosering van het middel individueel kan worden
aangepast) te vergemakkelijken en die tevens niet belastend zijn voor de patie¨nt.
In e´e´n studie hebben we de blootstelling aan het antischimmelmiddel fluconazol
gee¨valueerd in 99 ernstig zieke kinderen. Daarnaast hebben we gekeken naar de re-
latie tussen de blootstelling, door middel van de fluconazolconcentratie in het bloed
te meten, en de tijd die het kostte totdat de schimmel niet meer werd aangetoond in
het lichaam (i.e. niet meer kon worden gekweekt). De studie liet zien dat de flucona-
zolconcentratie onvoldoende hoog was in 40% van de patie¨nten. Bij gebruik van de
huidige aanbevolen dosering was de fluconazolblootstelling significant lager in kin-
deren met kanker dan in kinderen met een andere onderliggende aandoening. Ook
waren bij een hogere fluconazolconcentratie in het bloed de kweken eerder negatief.
In het algemeen kunnen we dus stellen dat de fluconazolconcentratie bij kinderen
met kanker, die behandeld worden met de huidige aanbevolen dosering, niet ade-
quaat is en dat kinderen in deze groep een hogere dosering nodig hebben. Er zal een
nieuwe dosering vastgesteld moeten worden, zodat ook bij kinderen met kanker een
adequate blootstelling aan fluconazol wordt bereikt. Tevens kan therapeutic drug
monitoring van fluconazol waardevol zijn om mogelijke onderbehandeling met flu-
conazol in ernstig zieke kinderen snel te kunnen detecteren.
Kinderen zijn vaak bang voor naalden en bloedprikken is bij kleine kinderen
vaak lastig. Om deze reden hebben we een analysemethode ontwikkeld waarmee
fluconazol in speeksel bepaald kan worden. De fluconazolconcentratie in speek-
sel kwam goed overeen met de concentratie in bloed en de monsters waren stabiel
bij kamertemperatuur voor tenminste 17 dagen. Het nemen van speekselmonsters
kan een niet-belastend en pijnloos alternatief zijn bij kinderen als bloedafname niet
wenselijk of niet mogelijk is. Indien patie¨nten langere tijd behandeld moeten wor-
den met antischimmelmiddelen en fluconazol thuis gebruiken, kan met behulp van
deze methode therapeutic drug monitoring ook in de thuissituatie worden uitge-
voerd.
In een tweede studie hebben we de blootstelling aan posaconazol gee¨valueerd
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in 70 volwassen patie¨nten met kanker en patie¨nten die een orgaantransplantatie
hebben ondergaan. In deze studie hebben we risicofactoren voor onderbehande-
ling met posaconazol gedetecteerd en hebben we gekeken naar de relatie van de
posaconazolblootstelling met het resultaat van de behandeling. De blootstelling
aan posaconazol in de vorm van een drankje was onvoldoende hoog in 40% van
de patie¨nten met een ernstige schimmelinfectie. Risicofactoren voor onderbehan-
deling waren een vloeibaar dieet, niet kunnen eten, overgeven, het gebruik van ge-
neesmiddelen die de pH van de maag beı¨nvloeden (zoals maagzuurremmers) en
het gelijktijdig krijgen van chemotherapie. Een hogere posaconazolconcentratie in
het bloed was gerelateerd aan een beter resultaat van de behandeling. Op basis van
onze resultaten en andere recente publicaties bevelen wij aan de posaconazoldrank
niet meer te geven aan patie¨nten die niet kunnen eten of die medicatie gebruiken die
de pH van de maag beı¨nvloeden. Met de ontwikkeling van een tablet en een infuus
zijn er alternatieven op de markt gekomen die geschikt zijn voor patie¨nten met een
verminderde voedselinname, absorptieproblemen en patie¨nten die maagzuurrem-
mers gebruiken. Met de verschillende toedieningsvormen van posaconazol kan, in
combinatie met therapeutic drug monitoring in geval van de drank, een adequate
blootstelling worden bereikt. Dit maakt posaconazol een waardevolle toevoeging
aan de antischimmelmiddelen die op dit moment beschikbaar zijn.
Om therapeutic drug monitoring van posaconazol, fluconazol en voriconazol
(de azolen) te vergemakkelijken hebben we een bloedspotmethode ontwikkeld waar-
bij de concentratie van het geneesmiddel wordt bepaald in e´e´n druppel bloed verkre-
gen door middel van een vingerprik. De bloedspotconcentraties van posacona-
zol, fluconazol en voriconazol in volwassen patie¨nten kwamen goed overeen met
de concentraties verkregen via bloedafname uit de arm en de bloedspotmonsters
waren stabiel bij kamertemperatuur voor tenminste 12 dagen. De meerderheid van
de patie¨nten gaf de voorkeur aan bloedspotafname boven de normale bloedafname
via de arm. Voordelen van de bloedspotmethode waren significant minder pijn bij
de afname van het monster en het niet hoeven reizen naar het ziekenhuis voor
bloedafname. Met behulp van deze bloedspotmethode kunnen de mogelijkheden
van therapeutic drug monitoring van de azolen worden uitgebreid naar patie¨nten
in de thuissituatie en naar ziekenhuizen met minder uitgebreide analytische mo-
gelijkheden.
Tenslotte hebben we voor het bepalen van caspofunginconcentraties in bloed een
nieuwe analysemethode ontwikkeld. Vervolgens hebben we in meerdere zieken-
huizen de farmacokinetiek en de caspofunginblootstelling gee¨valueerd in patie¨nten
met (een verdenking op) een ernstige schimmelinfectie met Candida die op de in-
tensive care lagen. Tussentijdse analyse van deze studie liet zien dat de caspo-
funginblootstelling in intensive care patie¨nten laag was in vergelijking met gezonde
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vrijwilligers en andere (minder zieke) patie¨nten. De lage caspofunginconcentratie
was waarschijnlijk het gevolg van een groter verdelingsvolume bij de patie¨nten op
de intensive care. Daarnaast was de blootstelling laag in patie¨nten in bepaalde
gewichtsklassen en bij patie¨nten met een leverbeschadiging die een lagere caspo-
fungindosering kregen. Dit hebben we ook eerder in een case report beschreven.
Onze bevindingen suggereren dat deze patie¨nten mogelijk een hogere caspofungin-
dosering nodig hebben, hoewel meer onderzoek nodig is om bewijs te verzamelen
voor de ontwikkeling van een nieuw doseringsregime voor deze patie¨ntengroep.
Met deze nieuwe doseringsaanbevelingen en de toevoeging van therapeutic drug
monitoring bij bepaalde patie¨nten, kan ook in patie¨nten op de intensive care snel
na start van de behandeling met caspofungin een adequate blootstelling aan het
geneesmiddel worden bereikt.
In dit proefschrift hebben we laten zien dat de blootstelling aan verschillende
antischimmelmiddelen vaak onvoldoende is in ernstig zieke volwassenen en kin-
deren waarbij de standaarddosering wordt gegeven. Een adequate blootstelling is
essentieel voor een effectieve behandeling en dus voor een beter resultaat van de
behandeling. Onze bevindingen laten zien dat er een meer geı¨ndividualiseerde be-
handeling moet worden ontwikkeld voor patie¨nten met een ernstige schimmelinfec-
tie. Deze behandeling zou gebaseerd moeten zijn op de kenmerken van de schim-
mel (soort schimmel, minimale concentratie die nodig is om de groei van de schim-
mel te remmen en locatie van de infectie) en op de kenmerken van de patie¨nt (on-
derliggende aandoening en behandeling van die aandoening, leidend tot een ver-
anderde absorptie, distributie, metabolisme en uitscheiding van het geneesmiddel).
Samen geven deze kenmerken informatie over de geschikte antischimmelbehan-
deling voor de individuele patie¨nt waarbij een optimale blootstelling aan het ge-
neesmiddel wordt verkregen en waarbij onnodige, niet-effectieve therapie of een
te hoge dosering, met bijwerkingen als gevolg, kunnen worden vermeden. Met
behulp van deze strategie is het mogelijk de behandeling van patie¨nten met een




at ik ooit een promotieonderzoek wilde doen wist ik al langer, maar toen ik een
paar jaar geleden de kans kreeg ben ik ervoor gegaan. Ik heb de afgelopen jaren
niet alleen veel geleerd, maar ook veel nieuwe vrienden gemaakt. Kortom, ik had
het niet willen missen. Hierbij wil ik iedereen bedanken die me de afgelopen jaren
gesteund en geholpen heeft bij het uitvoeren van mijn promotieonderzoek.
Prof. dr. Kosterink, Jos, als promotor bewaakte jij de grote lijnen van het onder-
zoek. Je liet me daarbij vrij om mijn onderzoek uit te voeren op de manier die voor
mij goed werkte. Je keek altijd met een realitische blik naar de planning en, ondanks
je eigen drukke schema, wist je dat er naast het werk ook andere dingen belangrijk
zijn. Als er problemen waren dacht jij altijd gelijk aan een oplossing, het onderzoek
kon zo in een mooi tempo doorgaan, bedankt!
Prof. dr. van der Werf, Tjip, het was erg fijn om ook een expert uit de klini-
sche praktijk op het gebied van infectieziekten als promotor te hebben. Vanuit deze
invalshoek kwam je altijd met nuttig commentaar en was je daardoor een mooie
aanvulling op het apothekersteam. Je bent altijd scherp en enthousiast en je weet
goed hoe je iemand kunt motiveren met je positieve instelling. Naast je inhoude-
lijke bijdrage hield je gelukkig ook wel van een geintje. Een high five lijkt me een
passende afsluiter van mijn promotie en onze fijne samenwerking!
Prof. dr. Uges, Donald, behalve dat jij mijn promotor bent, heb ik ook een aantal
jaar bij jou op het lab gewerkt. Ik ben mede door jou enthousiast geworden voor
het onderzoek en dat ik iets met therapeutic drug monitoring zou gaan doen stond
natuurlijk als een paal boven water. Daarnaast betrok je me altijd bij alles op het lab.
Ik heb daardoor niet alleen veel van je geleerd maar ook een fijne tijd gehad. Saai
was het nooit! Ik denk dat van alles wat ik van je geleerd heb ik de rest van mijn
carrie`re nog profijt zal hebben. Bedankt voor alles!
Dr. Alffenaar, Jan-Willem, als copromotor en dagelijkse begeleider hadden we
veel contact. Het is bewonderenswaardig hoe jij altijd positief blijft en kansen ziet
in plaats van moeilijkheden. Ik kon bij je terecht als dat nodig was (volgens mij had
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je zelfs ’s nachts nog opgenomen), maar je hebt me ook vrij gelaten om mijn eigen
ding te doen. Deze combinatie werkte erg goed. Bedankt voor de begeleiding en je
vertrouwen.
Prof. dr. Evelien de Bont, prof. dr. Ron Mathoˆt en prof. dr. Paul Verweij, bedankt
voor het beoordelen van mijn proefschrift als leden van de leescommissie.
Dr. Span en dr. Scho¨lvinck, Bart en Liesbeth, jullie waren als hematoloog en
kinderinfectioloog betrokken bij mijn onderzoek. Jullie bijdrage aan de onderzoeken
en de artikelen waren erg waardevol. Ik heb veel bewondering voor hoe jullie om-
gaan met het behandelen van ernstig zieke patie¨nten. Ze zijn bij jullie in goede
handen. Bedankt voor de fijne samenwerking!
Prof. dr. van den Heuvel, Edwin, zoals ik in e´e´n van mijn stellingen al aangeef
is het ook goed te weten wat je niet kunt. Vandaar dat ik al snel bij jou voor de deur
stond voor hulp bij de statistiek van mijn onderzoek. Toen ik op je deur de poster
zag met daarop ’keep calm and call a statician’ wist ik dat ik aan het goede adres
was. Bedankt voor al je hulp bij de statistiek en vooral ook voor dat je me zelf de
dingen in hebt laten zien. Ik heb er veel van geleerd en weet nu meer van statistiek
dan ik ooit had gedacht.
Prof. dr. Zijlstra, als we in de ziekenhuisapotheek onderzoek wilden doen op de
intensive care stonden jullie daar altijd voor open. Bedankt voor de goede samen-
werking bij de caspofungin- en micafunginstudie!
Dr. Dieperink, Wim, we konden altijd bij je terecht als we een studie op de in-
tensive care wilden doen. Als ik je zag maakte we vaak even een gezellig praatje.
En dankzij jou was ik ook op de hoogte van de gebruiken op de IC en bijnamen van
sommige mensen. Je weet het niet, maar bij ons in de apotheek is jouw bijnaam ’die
aardige man van de IC’, op z’n Gronings gezegd: het kon slechter.
Ook wil ik alle researchverpleegkundigen van de IC bedanken voor de hulp
bij mijn studies. Marisa, Ellen, Hildegard, Hetty, Frank, Tineke, Jurrie en Arnold,
dankzij jullie hulp is alles een stuk soepeler verlopen!
Voor de caspofunginstudie hebben we samengewerkt met de intensive care van
het Medisch Spectrum Twente. Ik wil dr. Beishuizen, dr. Klont en researchver-
pleegkundigen Martin en Mariska bedanken voor deze samenwerking.
Dr. Roger Bru¨ggemann, jij was mede-auteur bij mijn eerste artikel op het gebied
van schimmelinfecties. Ook daarna hadden we af en toe contact over het schimmel-
onderzoek. Bedankt voor je altijd waardevolle opmerkingen.
Marjolijn de Hooge, Manouche van Alst, Michael Rodgers en Karin Vermeulen,
bedankt voor jullie bijdrage aan het onderzoek en de artikelen.
Marieke, Hanneke, Charlie & Jasper, tijdens jullie masteronderzoek bij farmacie
heb ik jullie begeleid en hebben jullie een bijdrage aan mijn onderzoek geleverd. Het
heeft twee mooie publicatie’s over fluconazol en posaconazol opgeleverd. Bedankt
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voor jullie hulp! Jasper, succes met het afronden van de micafunginstudie!
Alle analisten van het laboratorium van de ziekenhuisapotheek, bedankt voor
jullie bijdrage aan mijn onderzoek en de gezellige tijd die ik als labapotheker bij jul-
lie heb gehad! Ben, bedankt dat ik met mijn onderzoeken altijd op het lab terecht
kon. Kai, bedankt voor je bijdrage op analytisch vlak aan mijn onderzoek. Ik hoefde
nooit lang te wachten op resultaten en als we nog weer wat extra’s hadden bedacht
was jij nooit te beroerd dit nog even te doen. Remco, voor analytische vragen kon
ik ook bij jou terecht. Handig dat jij op een gegeven moment ook ging promoveren,
je hebt het supersnel gedaan! Mireille, monsters raken natuurlijk nooit kwijt, maar
stel, hypothetisch gezien, dat het toch een keer zou gebeuren dan zou jij ze wel weer
boven tafel krijgen. Erwin, het viel niet mee met de analysemethode voor de mica-
funginstudie, maar zo heb je wel na je promotieonderzoek nog wat te publiceren.
Hiltjo (a.k.a Hillie B.), bedankt voor de gezellige tijd op ’ons’ kantoor. Jan, Gerben,
Albert-Jan, Tanja, Annalie, Ingrid, Stefan, Justine en Ellen, doordat jullie altijd klaar
stonden voor de patie¨ntmonsters en de farmaceutische controle konden weer an-
dere mensen aan het onderzoek werken. Zonder jullie was dat niet gelukt! Bedankt
ook voor de gezellige kofffiepauzes! Pauline en Renella, dankzij jullie lekkere en
gezonde gebakjes ben ik mijn promotieonderzoek goed doorvoed doorgekomen ;-).
Maar vooral bedankt voor de gezelligheid en leuke gesprekken!
Jacqueline, Petra en Irene, als ik data uit het EVS nodig had kon ik bij jullie
terecht. En ook gewoon voor de gezelligheid! Bedankt ladies!
Bouwien, als ik een bepaald artikel nodig had wist jij deze altijd te vinden. Maar
ook voor een goed gesprek kon ik bij je langs. Bedankt voor je belangstelling en de
fijne gesprekken!
Annemiek, Wianda en Jessica, bedankt voor alle ondersteuning bij mijn onder-
zoek. Op z’n Vlaams gezegd: gij zijt het hart van de apotheek, amai!
Alle (oud-)apothekers, Prashant (de stage bij jou heeft mijn interesse in infec-
tieziekten alleen maar vergroot), Hendrikus, Barbara, Susan, Wouter (bedankt voor
de introductie van de ’golden rule’), Minke, Anton, Bob, Marina, Derk, Daan, Jan,
Silvia, Reinout, Eli, Esther, Rosalie, Nour, Marian, Marijn, Gea, Bart, Joke, Lisanne,
Mathieu (we zien elkaar op Strava), Coba, Mathijs, Annelies, Jasperien, Aileen,
Marieke en Marjolijn (het is altijd fijn om even te sparren met je medepromovendi,
of om gewoon even tegen elkaar te kunnen klagen).
De collega’s van de 5e verdieping Lubbert, Isaak, Marjan en Nanda, en Iemke,
Bob, Hilma en Hermien, bedankt voor jullie steun en belangstelling!
Ook wil ik mijn nieuwe collega’s van de Ziekenhuisgroep Twente bedanken. Fijn
dat jullie mij de ruimte hebben gegeven om het laatste stuk van mijn proefschrift af
te ronden. Dat had ik net even nodig! Ik ben erg blij met zulke leuke collega’s!
De Raad van Bestuur Ziekenhuisgroep Twente wil ik bedanken voor de financie¨le
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bijdrage aan het proefschrift.
Anet, sinds jij in het UMCG bent komen werken nam jij mijn studies over als ik
er niet was. Uiteraard dienden de patie¨nten zich dan altijd spontaan aan. Gelukkig
waren ze bij jou in goede handen. Nu ik weg ben zorg jij voor de verdere inclusie
van de caspofunginstudie. Daar hoef ik me dus geen zorgen over te maken. Bedankt
en succes met je eigen promotie!
Frank-Jan en Eva, jullie waren mijn medepromovendi en kamergenoten tijdens
de laatste 1,5 jaar van mijn promotieonderzoek. Het was erg fijn met zulke be-
gripvolle en gezellige collega-vrienden op de kamer te zitten. Jullie steun heeft mijn
promotie zeker goed gedaan. Ik kon met jullie lachen en huilen, gelukkig was het
vooral huilen van het lachen! Bedankt voor de fijne tijd en succes met de afronding
van jullie eigen promotie, dat komt helemaal goed!
Ricky Martin, bedankt voor de muzikale ondersteuning tijdens het schrijven van
mijn proefschrift. Muchas gracias!
Arianna, in de tijd met jou als kamergenoot en onze duobaan als labapotheker
was het erg gezellig en hebben we ook veel geleerd. De combinatie promotieonder-
zoek en werken als apotheker viel niet altijd mee, maar mede dankzij de boedisti-
sche levensspreuken die we op een gegeven moment ontdekt hebben (keep karma
keep calm, chop wood and carry water) is het ons gelukt. Na heel wat wood ge-
chopt te hebben en water gecarried is het dan nu zo ver, een afgeronde promotie!
Die nemen ze ons niet meer af ;-). Nu is het tijd voor ’een stukkie rust’. Bedankt
voor je steun en fijn dat je mijn paranimf wilt zijn.
Annette, toen we elkaar tijdens de studie ontmoet hebben klikte het gelijk. Tij-
dens de studie, maar ook daarna, heb jij me altijd gesteund. Je bent een van de
meest begripvolle mensen die ik ken. Ik kan alles bij je kwijt (het liefst natuurlijk
tijdens een lekker etentje, onze gezamelijke hobby ;-)). Ik ben erg blij met zo’n lieve
vriendin! Bij het begin van mijn promotieonderzoek wist ik nog niet hoe het alle-
maal zou lopen, maar ik wist al wel dat als het zo ver was jij mijn paranimf zou
zijn.
Ook wil ik mijn familie en de rest van mijn vrienden bedanken voor hun steun en
belangstelling tijdens mijn promotieonderzoek: opa & oma, mijn ouders, Raymond
& Baukje, mijn schoonfamilie, Heleen & Martin, Kees & Monique, Jan & Ineke,
Patricia & Wim, Maarten, Jan & Thirza, Steven, Judith en Ruby, bedankt voor alle
gezelligheid en fijn dat we al zo lang vrienden zijn!
Lieve Frank, jij bent er altijd voor me, wat er ook is. Ook tijdens mijn promotieon-
derzoek heb je me gesteund en geholpen. Daarnaast stimuleer je me om alles uit
mezelf te halen en geloof je altijd in me. Ik ben heel gelukkig met je en kijk uit naar
de rest van ons leven als doctor & doctor Bakker.
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